

CRYSTALLINE PEPTIDE EPOXY KETONE PROTEASE INHIBITORS AND THE SYNTHESIS OF AMINO ACID KETO-EPOXIDES

Related Applications

This application claims the benefit of priority of U.S. Provisional Patent
5 Application Serial No. 60/997,613 filed on October 4, 2007 and U.S. Provisional Patent
Application Serial No. 61/008,987 filed on December 20, 2007, the teachings of which
are incorporated by reference in their entirety.

Background of the Invention

In eukaryotes, protein degradation is predominately mediated through the
10 ubiquitin pathway in which proteins targeted for destruction are ligated to the 76 amino
acid polypeptide ubiquitin. Once targeted, ubiquitinated proteins then serve as substrates
for the 26S proteasome, a multicatalytic protease, which cleaves proteins into short
peptides through the action of its three major proteolytic activities. While having a
general function in intracellular protein turnover, proteasome-mediated degradation also
15 plays a key role in many processes such as major histocompatibility complex (MHC)
class I antigen presentation, apoptosis, cell growth regulation, NF- κ B activation, antigen
processing, and transduction of pro-inflammatory signals.

The 20S proteasome is a 700 kDa cylindrical-shaped multicatalytic protease
complex comprised of 28 subunits organized into four rings. In yeast and other
20 eukaryotes, 7 different α subunits form the outer rings and 7 different β subunits comprise
the inner rings. The α subunits serve as binding sites for the 19S (PA700) and 11S
(PA28) regulatory complexes, as well as a physical barrier for the inner proteolytic
chamber formed by the two β subunit rings. Thus, in vivo, the proteasome is believed to
exist as a 26S particle ("the 26S proteasome"). In vivo experiments have shown that
25 inhibition of the 20S form of the proteasome can be readily correlated to inhibition of 26S
proteasome. Cleavage of amino-terminal prosequences of β subunits during particle
formation expose amino-terminal threonine residues, which serve as the catalytic
nucleophiles. The subunits responsible for catalytic activity in proteasomes thus possess
an amino terminal nucleophilic residue, and these subunits belong to the family of N-
30 terminal nucleophile (Ntn) hydrolases (where the nucleophilic N-terminal residue is, for
example, Cys, Ser, Thr, and other nucleophilic moieties). This family includes, for


example, penicillin G acylase (PGA), penicillin V acylase (PVA), glutamine PRPP
amidotransferase (GAT), and bacterial glycosylasparaginase. In addition to the
ubiquitously expressed β subunits, higher vertebrates also possess three interferon- γ -
inducible β subunits (LMP7, LMP2 and MECL1), which replace their normal
5 counterparts, X, Y and Z respectively, thus altering the catalytic activities of the
proteasome. Through the use of different peptide substrates, three major proteolytic
activities have been defined for the eukaryote 20S proteasome: chymotrypsin-like
activity (CT-L), which cleaves after large hydrophobic residues; trypsin-like activity (T-
L), which cleaves after basic residues; and peptidylglutamyl peptide hydrolyzing activity
10 (PGPH), which cleaves after acidic residues. Two additional less characterized activities
have also been ascribed to the proteasome: BrAAP activity, which cleaves after
branched-chain amino acids; and SNAAP activity, which cleaves after small neutral
amino acids. The major proteasome proteolytic activities appear to be contributed by
different catalytic sites, since inhibitors, point mutations in β subunits and the exchange
15 of γ interferon-inducing β subunits alter these activities to various degrees.

What is needed are improved compositions and methods for preparing and
formulating proteasome inhibitor(s).

Summary of the Invention

The invention generally relates to the synthesis of proteasome inhibitors and the
20 preparation and purification of intermediates useful therefor.

One aspect of the invention relates to crystalline compounds having a structure of
Formula (I) or a pharmaceutically acceptable salt thereof,



I

25 wherein

X is O, NH, or N-alkyl, preferably O;

Y is NH, N-alkyl, O, or $C(R^9)_2$, preferably N-alkyl, O, or $C(R^9)_2$;

Z is O or $C(R^9)_2$, preferably $C(R^9)_2$;


R^1 , R^2 , R^3 , and R^4 are hydrogen;

each of R^5 , R^6 , R^7 , R^8 , and R^9 is independently selected from hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} alkoxyalkyl, aryl, and C_{1-6} aralkyl, each of which is optionally substituted with a group selected from alkyl, amide, amine, carboxylic acid or a pharmaceutically acceptable salt thereof, carboxyl ester, thiol, and thioether, preferably R^5 , R^6 , R^7 , and R^8 are independently selected from C_{1-6} alkyl, C_{1-6} hydroxyalkyl, and C_{1-6} aralkyl and each R^9 is hydrogen, more preferably, R^6 and R^8 are independently C_{1-6} alkyl, R^5 and R^7 are independently C_{1-6} aralkyl and each R^9 is H;

m is an integer from 0 to 2; and

10 n is an integer from 0 to 2, preferably 0 or 1.


Another aspect of the invention relates to a crystalline compound of Formula (III)



(III)

wherein X is any suitable counterion.

15 Another aspect of this invention relates to methods for the synthesis of amino acid keto-epoxides according to scheme (I)



(I)

wherein

20 R^1 is selected from a protecting group or a further chain of amino acids, which itself may be optionally substituted, preferably a protecting group, most preferably an electron withdrawing protecting group;

R^2 is selected from hydrogen and C_{1-6} alkyl;

R³ is selected from hydrogen, C₁₋₆alkyl, C₁₋₆alkoxyalkyl, heterocyclyl, aryl, heteroaryl, C₁₋₆heteroaralkyl, and C₁₋₆aralkyl; and

wherein the method comprises a stereoselective epoxidation under epoxidizing conditions, preferably an aqueous sodium hypochlorite (bleach) or calcium hypochlorite solution in the presence of a cosolvent selected from pyridine, acetonitrile, dimethylformamide (DMF), dimethylsulfoxide (DMSO), N-methylpyrrolidine (NMP), dimethylacetamide (DMA), tetrahydrofuran (THF), and nitromethane.

Brief Description of the Figures

Figure 1 shows a DSC (differential scanning calorimetry) thermogram of crystalline compound **1**.

Figure 2 shows an XRPD (X-ray powder diffraction) pattern of crystalline compound **1**.

Figure 3 shows a TG thermogram of crystalline compound **1**.

Figure 4 shows a DSC thermogram of amorphous compound **1** compared to a DSC thermogram of crystalline compound **1**.

Figure 5 shows an XRPD pattern of amorphous compound **1** compared to the XRPD pattern of crystalline compound **1**.

Figure 6 shows a TG thermogram of amorphous compound **1** compared to the TG pattern of crystalline compound **1**.

Figure 7 shows a DSC curve of an amorphous sample of compound **1**.

Figure 8 shows the XRPD pattern of amorphous compound **1**.

Figure 9 shows a DSC curve of a crystalline compound F.


Figure 10 shows an XRPD pattern of a crystalline compound F.

Figure 11 shows a DSC curve of a crystalline citrate salt of compound **1**.

Figure 12 shows an XRPD pattern of a crystalline citrate salt of compound **1**.

Detailed Description of the Invention

In certain embodiments, the invention relates to crystalline compounds having a structure of Formula (I) or a pharmaceutically acceptable salt thereof,



I

wherein

X is O, NH, or N-alkyl, preferably O;

Y is NH, N-alkyl, O, or C(R⁹)₂, preferably N-alkyl, O, or C(R⁹)₂;

Z is O or C(R⁹)₂, preferably C(R⁹)₂;

10 R¹, R², R³, and R⁴ are hydrogen;

each of R⁵, R⁶, R⁷, R⁸, and R⁹ is independently selected from hydrogen, C₁₋₆alkyl, C₁₋₆hydroxyalkyl, C₁₋₆alkoxyalkyl, aryl, and C₁₋₆aralkyl, each of which is optionally substituted with a group selected from alkyl, amide, amine, carboxylic acid or a pharmaceutically acceptable salt thereof, carboxyl ester, thiol, and thioether, preferably R⁵, R⁶, R⁷, and R⁸ are independently selected from C₁₋₆alkyl, C₁₋₆hydroxyalkyl, and C₁₋₆aralkyl and each R⁹ is hydrogen, more preferably, R⁶ and R⁸ are independently C₁₋₆alkyl, R⁵ and R⁷ are independently C₁₋₆aralkyl and each R⁹ is H;

m is an integer from 0 to 2; and

n is an integer from 0 to 2, preferably 0 or 1.


20 In certain embodiments, X is O and R¹, R², R³, and R⁴ are all the same, preferably R¹, R², R³, and R⁴ are all hydrogen. In certain such embodiments, R⁵, R⁶, R⁷, and R⁸ are independently selected from C₁₋₆alkyl, C₁₋₆hydroxyalkyl, and C₁₋₆aralkyl, more preferably, R⁶ and R⁸ are independently C₁₋₆alkyl and R⁵ and R⁷ are independently C₁₋₆aralkyl.

25 In certain preferred embodiments, X is O, R¹, R², R³, and R⁴ are all hydrogen, R⁶ and R⁸ are both isobutyl, R⁵ is phenylethyl, and R⁷ is phenylmethyl.

In certain embodiments, R^5 , R^6 , R^7 , and R^8 are independently selected from hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} alkoxyalkyl, aryl, and C_{1-6} aralkyl, each of which is optionally substituted with a group selected from alkyl, amide, amine, carboxylic acid or a pharmaceutically acceptable salt thereof, carboxyl ester, thiol, and thioether. In certain embodiments, at least one of R^5 and R^7 is C_{1-6} aralkyl substituted with alkyl, more preferably substituted with perhaloalkyl. In certain such embodiments, R^7 is C_{1-6} aralkyl substituted with trifluoromethyl.

In certain embodiments, Y is selected from N-alkyl, O, and CH_2 . In certain such embodiments, Z is CH_2 , and m and n are both 0. In certain alternative such embodiments, Z is CH_2 , m is 0, and n is 2 or 3. In yet another alternative such embodiments, Z is O, m is 1, and n is 2.

In certain embodiments, the invention relates to a crystalline compound of Formula (II)



(II)

In certain embodiments, the invention relates to a method for the preparation of a crystalline compound of Formula (I) or (II), comprising one or more of: (i) preparing the amorphous compound, e.g., according to U.S. Patent No. 7,232,818; (ii) dissolving the amorphous compound in an organic solvent; (iii) bringing the solution to supersaturation to cause formation of crystals; and (iv) isolating the crystals, e.g., by filtering the crystals, by decanting fluid from the crystals, or by any other suitable separation technique. In certain embodiments, preparation further comprises inducing crystallization. In certain embodiments, preparation further comprises washing the filtered crystals, e.g., with a solvent or non-solvent fluid. In certain embodiments, preparation further comprises drying, preferably under reduced pressure, such as under vacuum pressure.

In certain embodiments, the invention relates to a method for the preparation of a crystalline compound of Formula (I) or (II), comprising one or more of: (i) preparing a solution of the amorphous compound, which compound may be prepared according to, for example, U.S. Patent No. 7,232,818, in an organic solvent; (ii) bringing the solution to
5 supersaturation to cause formation of crystals; and (iii) isolating the crystals, e.g., by filtering the crystals, by decanting fluid from the crystals, or by any other suitable separation technique. In certain embodiments, preparation further comprises inducing crystallization. In certain embodiments, preparation further comprises washing the filtered crystals, e.g., with a solvent or non-solvent fluid. In certain embodiments,
10 preparation further comprises drying, preferably under reduced pressure, such as under vacuum pressure.

In certain embodiments, the amorphous compound may be dissolved in an organic solvent selected from acetonitrile, methanol, ethanol, ethyl acetate, isopropanol, isopropyl acetate, isobutyl acetate, butyl acetate, propyl acetate, methylethyl ketone, methylisobutyl
15 ketone, and acetone, or any combination thereof. In certain embodiments, the amorphous compound may be dissolved in an organic solvent selected from acetonitrile, methanol, ethanol, ethyl acetate, isopropyl acetate, methylethyl ketone, and acetone, or any combination thereof. In certain embodiments, the amorphous compound may be dissolved in an organic solvent selected from acetonitrile, methanol, ethanol, ethyl
20 acetate, methylethylketone, or any combination thereof. In certain embodiments, the organic solvent or solvents may be combined with water.

In certain embodiments, bringing the solution to supersaturation comprises the addition of an anti-solvent, such as water or another polar liquid miscible with the organic solvent, allowing the solution to cool, reducing the volume of the solution, or any
25 combination thereof. In certain embodiments, bringing the solution to supersaturation comprises adding an anti-solvent, cooling the solution to ambient temperature or lower, and reducing the volume of the solution, e.g., by evaporating solvent from the solution. In certain embodiments, allowing the solution to cool may be passive (e.g., allowing the solution to stand at ambient temperature) or active (e.g., cooling the solution in an ice
30 bath or freezer).

In certain embodiments, the method further comprises inducing precipitation or crystallization. In certain embodiments inducing precipitation or crystallization

comprises secondary nucleation, wherein nucleation occurs in the presence of seed crystals or interactions with the environment (crystallizer walls, stirring impellers, sonication, etc.).

5 In certain embodiments, washing the crystals comprises washing with a liquid selected from anti-solvent, acetonitrile, methanol, ethanol, ethyl acetate, methylethyl ketone, acetone, or a combination thereof. Preferably the crystals are washed with a combination of anti-solvent and the organic solvent. In certain embodiments, the anti-solvent is water.

10 In certain embodiments, washing the crystals comprises washing the crystalline compound of Formula (II) with methanol and water.

In certain embodiments, a crystalline compound of Formula (II) is substantially pure. In certain embodiments, the melting point of the crystalline compound of Formula (II) is in the range of about 200 to about 220 °C, about 205 to about 215 °C, about 211 to about 213 °C, or even about 212 °C.

15 In certain embodiments, the DSC of a crystalline compound of Formula (II) has a sharp endothermic maximum at about 212 °C, e.g., resulting from melting and decomposition of the crystalline form as shown in Figure 1.

20 In certain embodiments, the X-ray powder pattern of a crystalline compound of Formula (II) is (θ -2 θ°): 6.10; 8.10; 9.32; 10.10; 11.00; 12.14; 122.50; 13.64; 13.94; 17.14; 17.52; 18.44; 20.38; 21.00; 22.26; 23.30; 24.66; 25.98; 26.02; 27.84; 28.00; 28.16; 29.98; 30.46; 32.98; 33.22; 34.52; 39.46 as shown in Figure 2.

In certain embodiments, the TG thermogram of a crystalline compound of Formula (II) exhibits from 0.0 to 0.1% weight loss in the temperature range of 25 to 200 °C as shown in Figure 3.

25 In certain embodiments, a crystalline compound of Formula (II) is not solvated (e.g., the crystal lattice does not comprise molecules of a solvent). In certain alternative embodiments, a crystalline compound of Formula (II) is solvated.

30 In certain embodiments, the invention relates to a method for the preparation of an amorphous compound of Formula (II) comprising one or more of (i) dissolving the crystalline compound in an organic solvent; (ii) bringing the solution to supersaturation to

cause formation of crystals; and (iii) isolating the crystals, e.g., by filtering the crystals, by decanting fluid from the crystals, or by any other suitable separation technique. In certain embodiments, preparation further comprises inducing precipitation. In certain
5 certain embodiments, preparation further comprises washing the amorphous compound. In certain embodiments, the method further comprises drying, preferably under reduced pressure, such as under vacuum pressure. In certain embodiments, the invention relates to a crystalline salt of a compound of Formula (I) or (II), wherein the salt counterion is selected from bromide, chloride, sulfate, phosphate, nitrate, acetate, trifluoroacetate, citrate, methanesulfonate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate,
10 succinate, tosylate, malonate, maleate, fumarate, succinate, tartrate, mesylate, 2-hydroxyethansulfonate, and the like. In certain such embodiments, the salt counterion is selected from citrate, tartrate, trifluoroacetate, methanesulfonate, toluenesulfonate, chloride, and bromide, preferably citrate.

In certain embodiments, the invention relates to a method for the preparation of a
15 crystalline salt of a compound of Formula (II), comprising one or more of: (i) preparing the amorphous compound e.g., according to U.S. Patent No. 7,232,818; (ii) dissolving the amorphous compound in an organic solvent; (iii) bringing the solution to supersaturation to cause formation of crystals; and (iv) isolating the crystals, e.g., by filtering the crystals, by decanting fluid from the crystals, or by any other suitable separation technique. In
20 certain embodiments, preparation further comprises inducing crystallization. In certain embodiments, preparation further comprises washing the crystals, e.g., with a solvent or non-solvent fluid. In certain embodiments, preparation further comprises drying, preferably under reduced pressure, such as under vacuum pressure.

In certain embodiments, the invention relates to a method for the preparation of a
25 crystalline salt of a compound of Formula (II), comprising one or more of (i) preparing a solution of a compound of Formula (II) in an organic solvent; (ii) adding a suitable acid; (iii) bringing the solution to supersaturation to cause formation of crystals; and (iv) isolating the crystals, e.g., by filtering the crystals, by decanting fluid from the crystals, or by any other suitable separation technique. In certain embodiments, preparation further
30 comprises inducing crystallization. In certain embodiments, preparation further comprises washing the crystals, e.g., with a solvent or non-solvent fluid. In certain embodiments, preparation further comprises drying, preferably under reduced pressure,

such as under vacuum pressure. In certain embodiments where the salt is less soluble in a solvent than the free base, adding the acid to a solution may itself be sufficient to bring the solution to supersaturation.

5 In certain embodiments, the salt counterion is selected from selected from
bromide, chloride, sulfate, phosphate, nitrate, acetate, trifluoroacetate, citrate,
methanesulfonate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate,
succinate, tosylate, malonate, maleate, fumarate, succinate, tartrate, mesylate, 2-
hydroxyethansulfonate, and the like. In certain such embodiments, the salt counterion is
selected from citrate, tartrate, trifluoroacetate, methanesulfonate, toluenesulfonate,
10 chloride, and bromide, preferably citrate.


In certain embodiments, the organic solvent is selected from THF, acetonitrile, ether, and MTBE, or any combination thereof, preferably THF or acetonitrile, or a combination thereof.

15 In certain embodiments, a crystalline citrate salt of a compound of Formula (II) is substantially pure. In certain embodiments, the melting point of the crystalline citrate salt of a compound of Formula (II) is in the range of about 180 to about 190 °C or even about 184 to about 188 °C.

20 In certain embodiments, the DSC of a crystalline citrate salt of a compound of Formula (II) has a sharp endothermic maximum at about 187 °C, e.g., resulting from melting and decomposition of the crystalline form as shown in Figure 11.

In certain embodiments, the X-ray powder pattern of a crystalline citrate salt of a compound of Formula (II) is (θ - $2\theta^\circ$): 4.40; 7.22; 9.12; 12.36; 13.35; 14.34; 15.54; 16.14; 16.54; 17.00; 18.24; 18.58; 19.70; 19.90; 20.30; 20.42; 21.84; 22.02; 23.34; 23.84; 24.04; 24.08; 24.48; 24.76; 25.48; 26.18; 28.14; 28.20; 28.64; 29.64; 31.04; 31.84; 33.00; 33.20; 25 34.06; 34.30; 34.50; 35.18; 37.48; 37.90; 39.48 as shown in Figure 12.

In certain embodiments, the invention relates to a crystalline compound of Formula (III)




(III)

wherein X is any suitable counterion.

In certain embodiments, X is a counterion selected from bromide, chloride,
 5 sulfate, phosphate, nitrate, acetate, trifluoroacetate, citrate, methanesulfonate, valerate,
 oleate, palmitate, stearate, laurate, benzoate, lactate, succinate, tosylate, malonate,
 maleate, fumarate, succinate, tartrate, mesylate, 2-hydroxyethansulfonate, and the like.
 (See, for example, Berge et al. (1977) "Pharmaceutical Salts", J. Pharm. Sci. 66: 1-19.)

In certain embodiments X is selected from trifluoroacetate, methanesulfonate,
 10 toluenesulfonate, acetate, chloride, and bromide, preferably trifluoroacetate.


In certain embodiments, the invention relates to a method for the preparation of a
 crystalline compound of Formula (III) comprising one or more of: (i) preparing a
 compound of Formula (IV), e.g., according to Bioorg. Med. Chem. Letter 1999, 9, 2283-
 88 or U.S. Patent Application 2005-0256324, wherein PG is a suitable protecting group
 15 (e.g., Boc or Cbz)



(IV)

(ii) dissolving the compound of Formula (IV) in an organic solvent; (iii) adding a suitable
 acid; (iv) bringing the solution to supersaturation to cause formation of crystals; and (v)
 20 isolating the crystals, e.g., by filtering the crystals, by decanting fluid from the crystals, or
 by any other suitable separation technique. In certain embodiments, preparation further
 comprises inducing crystallization. In certain embodiments, preparation further
 comprises washing the crystals, e.g., with a solvent or non-solvent fluid. In certain
 embodiments, preparation further comprises drying, preferably under reduced pressure,
 25 such as under vacuum pressure.

In certain embodiments, the invention relates to a method for the preparation of a crystalline compound of Formula (III), comprising one or more of: (i) preparing a solution of an amorphous compound of Formula (IV), e.g., according to Bioorg. Med. Chem. Letter 1999, 9, 2283-88 or U.S. Patent Application 2005-0256324, in an organic solvent, wherein PG is a suitable protecting group (e.g., Boc or Cbz).



(IV)

(ii) bringing the solution to supersaturation to cause formation of crystals; and (iii) isolating the crystals, e.g., by filtering the crystals, by decanting fluid from the crystals, or by any other suitable separation technique. In certain embodiments, preparation further comprises inducing crystallization. In certain embodiments, preparation further comprises washing the crystals, e.g., with a solvent or non-solvent fluid. In certain embodiments, preparation further comprises drying, preferably under reduced pressure, such as under vacuum pressure.

In certain embodiments the acid is selected from hydrobromic, hydrochloric, sulfuric, phosphoric, nitric, acetic, trifluoroacetic, citric, methanesulfonic, valeric, oleic, palmitic, stearic, lauric, benzoic, lactic, succinic, p-toluenesulfonic, citric, malonic, maleic, fumaric, succinic, tartaric, methanesulfonic, 2-hydroxyethanesulfonic, and the like. Preferably the acid is trifluoroacetic acid.

In certain embodiments, X is a counterion selected from hydrobromide, hydrochloride, sulfate, phosphate, nitrate, acetate, trifluoroacetate, citrate, methanesulfonate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, succinate, tosylate, malonate, maleate, fumarate, succinate, tartrate, mesylate, 2-hydroxyethansulfonate, and the like. (See, for example, Berge et al. (1977) "Pharmaceutical Salts", J. Pharm. Sci. 66: 1-19.) In certain embodiments, X is selected from trifluoroacetate, methanesulfonate, toluenesulfonate, acetate, chloride, and bromide, preferably trifluoroacetate.

In certain embodiments, the compound of Formula (IV) may be dissolved in an organic solvent selected from dichloromethane, ethyl acetate, isopropyl acetate, isobutyl acetate, butyl acetate, propyl acetate, diethyl ether, methyl tert-butyl ether (MTBE), or any combination thereof. In certain embodiments, the organic solvent is selected from
5 dichloromethane, ethyl acetate, MTBE, or any combination thereof, preferably either dichloromethane and MTBE or ethyl acetate and MTBE.

In certain embodiments, bringing the solution to supersaturation comprises the addition of an anti-solvent, such as hexanes or heptanes or another liquid miscible with the organic solvent, allowing the solution to cool, reducing the volume of the solution, or
10 any combination thereof. In certain embodiments, bringing the solution to supersaturation comprises adding an anti-solvent, cooling the solution to ambient temperature or lower, and reducing the volume of the solution, e.g., by evaporating solvent from the solution. In certain embodiments, the anti-solvent is hexanes or heptanes, preferably heptanes.


15 In certain embodiments, washing the crystals comprises washing with a liquid selected from anti-solvent, ethyl acetate, dichloromethane, or a combination thereof. Preferably the crystals are washed with anti-solvent, preferably heptanes.

In certain embodiments, the DSC of a crystalline compound of Formula (III) has a sharp endothermic maximum at about 137 °C, e.g., resulting from melting and
20 decomposition of the crystalline form as shown in Figure 9.

In certain embodiments, the X-ray powder pattern of a crystalline compound of Formula (II) is (θ -2 θ°): 8.84; 15.18; 15.32; 16.20; 16.82; 17.66; 18.26; 19.10; 21.20; 22.58; 23.06; 23.52; 25.32; 26.58; 28.60; 30.08; 30.48; 30.84; 32.20; 36.14; 37.12 as shown in Figure 10.


25 In certain embodiments, a crystalline compound of Formula (III) is not solvated (e.g., the crystal lattice does not comprise molecules of a solvent). In certain alternative embodiments, a crystalline compound of Formula (III) is solvated.

In certain embodiments, the invention relates to a method for the preparation of a crystalline compound of Formula (II), comprising one or more of (i) preparing a solution
30 of compound of Formula (IV) wherein PG is a suitable protecting group (e.g., Boc or Cbz), in a first organic solvent




(IV)

- (ii) adding a suitable acid; (iii) bringing the solution to supersaturation to cause formation of crystals; (iv) isolating the crystals to provide a crystalline compound of Formula (III);
 5 (v) reacting the crystalline compound of Formula (III)



(III)

wherein X is any suitable counterion, with a compound of Formula (V)



(V)

- to provide a compound of Formula (II); (vi) preparing a solution of the compound of Formula (II) in a second organic solvent; (vii) bringing the solution to supersaturation to cause formation of crystals; and (viii) isolating the crystals to provide a crystalline compound of Formula (II), e.g., by filtering the crystals, by decanting, or by any other
 15 suitable separation technique. In certain embodiments, preparation further comprises inducing crystallization. In certain embodiments, preparation further comprises washing the crystals, e.g., with a solvent or non-solvent fluid. In certain embodiments, preparation further comprises drying, preferably under reduced pressure, such as under vacuum pressure.

- 20 In certain embodiments, the acid is selected from hydrobromic, hydrochloric, sulfuric, phosphoric, nitric, acetic, trifluoroacetic, citric, methanesulfonic, valeric, oleic,

palmitic, stearic, lauric, benzoic, lactic, succinic, p-toluenesulfonic, citric, malonic, maleic, fumaric, succinic, tartaric, methanesulfonic, 2-hydroxyethanesulfonic, and the like. Preferably the acid is trifluoroacetic acid.

5 In certain embodiments, X is a counterion selected from hydrobromide, hydrochloride, sulfate, phosphate, nitrate, acetate, trifluoroacetate, citrate, methanesulfonate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, succinate, tosylate, malonate, maleate, fumarate, succinate, tartrate, mesylate, 2-hydroxyethanesulfonate, and the like. (See, for example, Berge et al. (1977) "Pharmaceutical Salts", J. Pharm. Sci. 66: 1-19.) In certain embodiments, X is selected
10 from trifluoroacetate, methanesulfonate, toluenesulfonate, acetate, chloride, and bromide, preferably trifluoroacetate.

In certain embodiments, the first organic solvent is selected from dichloromethane, ethyl acetate, isopropyl acetate, isobutyl acetate, butyl acetate, propyl acetate, diethyl ether, methyl tert-butyl ether (MTBE), or any combination thereof. In
15 certain embodiments, the organic solvent is selected from dichloromethane, ethyl acetate, MTBE, or any combination thereof, preferably either dichloromethane and MTBE or ethyl acetate and MTBE.

In certain embodiments, the second organic solvent is selected from acetonitrile, methanol, ethanol, ethyl acetate, isopropanol, isopropyl acetate, isobutyl acetate, butyl
20 acetate, propyl acetate, methylethyl ketone, methylisobutyl ketone, and acetone, or any combination thereof. In certain embodiments, the amorphous compound may be dissolved in an organic solvent selected from acetonitrile, methanol, ethanol, ethyl acetate, acetone, or any combination thereof. In certain embodiments, the organic solvent or solvents may be combined with water.


25 In certain embodiments, preparation further comprises washing the crystals of either or both of Formula (II) or (III). In certain embodiments, washing the crystals of a compound of Formula (II) comprises washing with a liquid selected from anti-solvent, acetonitrile, methanol, ethanol, ethyl acetate, acetone, or a combination thereof. Preferably the crystals of a compound of Formula (II) are washed with a combination of
30 anti-solvent and the organic solvent. In certain embodiments, washing the crystals comprises washing the crystalline compound of Formula (II) with methanol and water. In

certain embodiments, washing the crystals of a compound of Formula (III) comprises washing with a liquid selected from anti-solvent, ethyl acetate, dichloromethane, or a combination thereof. Preferably the crystals of a compound of Formula (III) are washed with anti-solvent, preferably heptanes.

5 In certain embodiments, preparation further comprises drying the crystals of either or both of Formula (II) or (III), preferably under reduced pressure, such as under vacuum pressure.

In certain embodiments, the invention relates to a pharmaceutical composition comprising a crystalline compound of Formula (I) or (II) and a pharmaceutically
10 acceptable carrier. In certain embodiments, the pharmaceutical composition is selected from tablets, capsules, and injections.

This invention also relates to methods for the synthesis of epoxyketones, such as formulae (III) and (IV) above. Thus, in another aspect, the invention provides a method for preparing amino acid keto-epoxides according to scheme (I)



wherein

R¹ is selected from a protecting group or a further chain of amino acids, which itself may be optionally substituted, preferably a protecting group, most preferably an
20 electron withdrawing protecting group;

R² is selected from hydrogen and C₁₋₆alkyl; and

R³ is selected from hydrogen, C₁₋₆alkyl, C₁₋₆alkoxyalkyl, heterocyclyl, aryl, heteroaryl, C₁₋₆heteroaralkyl, and C₁₋₆aralkyl; and

wherein the method comprises a stereoselective epoxidation under epoxidizing
25 conditions, preferably an aqueous sodium hypochlorite(bleach) or calcium hypochlorite solution in the presence of a cosolvent selected from pyridine, acetonitrile, DMF, DMSO, NMP, DMA, THF, and nitromethane.

In certain embodiments, the cosolvent is selected from NMP and pyridine, preferably pyridine.

In certain embodiments, the epoxidation is performed using aqueous sodium hypochlorite in the presence of a cosolvent selected from pyridine, acetonitrile, DMF, DMSO, NMP, DMA, THF, and nitromethane, preferably NMP or pyridine, more preferably pyridine. In certain embodiments, the epoxidation is performed using a 10% aqueous sodium hypochlorite solution. In certain embodiments, the epoxidation is performed using a 10% aqueous sodium hypochlorite solution in the presence of pyridine. In certain embodiments, the epoxidation is performed using a calcium hypochlorite solution in the presence of NMP.

In certain embodiments, R^1 is selected from a protecting group or a further chain of amino acids, which itself may be optionally substituted. In certain such embodiments, R^1 is a protecting group, preferably an electron withdrawing protecting group.


In certain embodiments, R^1 is selected from *t*-butoxy carbonyl (Boc), benzoyl (Bz), fluoren-9-ylmethoxycarbonyl (Fmoc), trichloroethoxycarbonyl (Troc), and benzyloxy carbonyl (Cbz). In certain such embodiments, R^1 is selected from *t*-butoxy carbonyl (Boc), benzoyl (Bz), trichloroethoxycarbonyl (Troc), and benzyloxy carbonyl (Cbz), preferably Cbz or Boc. In certain preferred embodiments, R^1 is Boc.

In certain embodiments, R^3 is selected from hydrogen, C_{1-6} alkyl, C_{1-6} alkoxyalkyl, heterocyclyl, aryl, heteroaryl, C_{1-6} heteroaralkyl, and C_{1-6} aralkyl. In preferred embodiments, R^3 is C_{1-6} alkyl, preferably isobutyl. In certain preferred embodiments, R^3 is C_{1-6} aralkyl, preferably phenylmethyl, 4-hydroxyphenylmethyl, or 2-phenylethyl.

In certain embodiments, the stereoselective epoxidation is performed under conditions that do not result in significant epimerization of the carbon bearing R^3 , such that there is less than 10%, less than 5%, less than 2%, or even less than 1% epimerization of the carbon bearing R^3 . In certain embodiments, the stereoselective epoxidation is performed such that the product is greater than about 90%, greater than 95%, greater than 98%, or even greater than 99% diastereomerically pure.

In certain embodiments, the epoxidation is performed at a temperature in the range of about -15 °C to about 10 °C, about -10 °C to about 5 °C, or even about -5 °C to about 0 °C.

In certain embodiments, the compounds in scheme I have the following stereochemistry




In certain embodiments, the stereoselective epoxidation is performed such that the product is greater than about 90%, greater than 95%, greater than 98%, or even greater than 99% diastereomerically pure.

The use of various N-protecting groups, e.g., the benzyloxy carbonyl group or the t-butyloxycarbonyl group (Boc), various coupling reagents, e.g., dicyclohexylcarbodiimide (DCC), 1,3-diisopropylcarbodiimide (DIC), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC), N-hydroxyazabenzotriazole (HATU), carbonyldiimidazole, or 1-hydroxybenzotriazole monohydrate (HOBT), and various cleavage conditions: for example, trifluoroacetic acid (TFA), HCl in dioxane, hydrogenation on Pd/C in organic solvents (such as methanol or ethyl acetate), boron tris(trifluoroacetate), and cyanogen bromide, and reaction in solution with isolation and purification of intermediates are well-known in the art of peptide synthesis, and are equally applicable to the preparation of the subject compounds (Greene, T.W.; Wuts, P.G.M. *Protective Groups in Organic Synthesis*, 3rd ed.; Wiley: New York, 1999).

In certain embodiments, the amino acid keto-epoxide may be further modified by deprotection of the amine, if applicable, and coupling with a chain of amino acids. Methods for the coupling of such fragments are well known in the art (Elofsson, M., et al. (1999) *Chemistry & Biology*, 6:811-822; Elofsson, M., et al (1999) *Chemistry & Biology*, 6:811-822). In a preferred embodiment, the chain of amino acids comprises one to three amino acids.

In certain embodiments, the chain of amino acids has a structure of formula (VI) or a pharmaceutically acceptable salt thereof



(VI)

- wherein each A is independently selected from C=O, C=S, and SO₂, preferably C=O; or
A is optionally a covalent bond when adjacent to an occurrence of Z;
L is absent or is selected from C=O, C=S, and SO₂, preferably L is absent or C=O;
M is absent or is C₁₋₁₂alkyl, preferably C₁₋₈alkyl;
- 5 Q is absent or is selected from O, NH, and N-C₁₋₆alkyl, preferably Q is absent, O, or NH,
most preferably Q is absent or O;
- X is COOH or an activated form thereof, preferably X is COOH, COCl, or
CON(Me)(OMe), most preferably X is COOH or COCl;
- Y is absent or is selected from O, NH, N-C₁₋₆alkyl, S, SO, SO₂, CHOR¹⁷, and CHCO₂R¹⁷;
- 10 each Z is independently selected from O, S, NH, and N-C₁₋₆alkyl, preferably O; or
Z is optionally a covalent bond when adjacent to an occurrence of A;
- R⁵, R⁶, and R⁷ are each independently selected from C₁₋₆alkyl, C₁₋₆hydroxyalkyl, C₁₋₆
alkoxyalkyl, aryl, and C₁₋₆aralkyl, any of which is optionally substituted with one
or more of amide, amine, carboxylic acid (or a salt thereof), ester (including C₁₋₆
15 alkyl and C₁₋₅alkyl ester and aryl ester), thiol, or thioether substituents;
- R⁹ is N(R¹⁰)LQR¹¹;
- R¹⁰, R¹², and R¹³ are independently selected from hydrogen, OH, and C₁₋₆alkyl,
preferably, R¹⁰ is selected from hydrogen, OH, and C₁₋₆alkyl, and R¹² and R¹³ are
independently selected from hydrogen and C₁₋₆alkyl, preferably hydrogen;
- 20 R¹¹ is selected from hydrogen, C₁₋₆alkyl, C₁₋₆alkenyl, C₁₋₆alkynyl, aryl, C₁₋₆aralkyl,
heteroaryl, C₁₋₆heteroaralkyl, R¹⁵ZAZ-C₁₋₈alkyl-, R¹⁸Z-C₁₋₈alkyl-,
(R¹⁵O)(R¹⁶O)P(=O)O-C₁₋₈alkyl-ZAZ-C₁₋₈alkyl-, R¹⁵ZAZ-C₁₋₈alkyl-ZAZ-C₁₋₈
alkyl-, heterocyclylMZA-C₁₋₈alkyl-, (R¹⁵O)(R¹⁶O)P(=O)O-C₁₋₈alkyl-, (R¹⁷)₂N-
C₁₋₁₂alkyl-, (R¹⁷)₃N⁺-C₁₋₁₂alkyl-, heterocyclylM-, carbocyclylM-, R¹⁸SO₂C₁₋₈alkyl-
25 , and R¹⁸SO₂NH; preferably C₁₋₆alkyl, C₁₋₆alkenyl, C₁₋₆alkynyl, aryl, C₁₋₆aralkyl,
heteroaryl, C₁₋₆heteroaralkyl, R¹⁵ZA-C₁₋₈alkyl-, R¹⁸Z-C₁₋₈alkyl-,
(R¹⁵O)(R¹⁶O)P(=O)O-C₁₋₈alkyl-ZAZ-C₁₋₈alkyl-, (R¹⁵O)(R¹⁶O)P(=O)O-C₁₋₈alkyl-
Z-C₁₋₈alkyl-, R¹⁵ZA-C₁₋₈alkyl-ZAZ-C₁₋₈alkyl-, heterocyclylMZA-C₁₋₈alkyl-,
(R¹⁵O)(R¹⁶O)P(=O)O-C₁₋₈alkyl-, (R¹⁷)₂N-C₁₋₈alkyl-, (R¹⁷)₃N⁺-C₁₋₈alkyl-,

heterocyclylM-, carbocyclylM-, $R^{18}SO_2C_{1-8}alkyl-$, and $R^{18}SO_2NH$, wherein each occurrence of Z and A is independently other than a covalent bond; or

5 R^{10} and R^{11} together are $C_{1-6}alkyl-Y-C_{1-6}alkyl$, $C_{1-6}alkyl-ZAZ-C_{1-6}alkyl$, $ZAZ-C_{1-6}alkyl-ZAZ-C_{1-6}alkyl$, $ZAZ-C_{1-6}alkyl-ZAZ$, or $C_{1-6}alkyl-A$, thereby forming a ring; preferably $C_{1-2}alkyl-Y-C_{1-2}alkyl$, $C_{1-2}alkyl-ZA-C_{1-2}alkyl$, $A-C_{1-2}alkyl-ZA-C_{1-2}alkyl$, $A-C_{1-3}alkyl-A$, or $C_{1-4}alkyl-A$, wherein each occurrence of Z and A is independently other than a covalent bond;

10 R^{15} and R^{16} are independently selected from hydrogen, metal cation, $C_{1-6}alkyl$, $C_{1-6}alkenyl$, $C_{1-6}alkynyl$, aryl, heteroaryl, $C_{1-6}aralkyl$, and $C_{1-6}heteroaralkyl$, preferably from hydrogen, metal cation, and $C_{1-6}alkyl$, or R^{15} and R^{16} together are $C_{1-6}alkyl$, thereby forming a ring;

each R^{17} is independently selected from hydrogen and $C_{1-6}alkyl$, preferably $C_{1-6}alkyl$;

R^{18} is independently selected from hydrogen, OH, $C_{1-6}alkyl$, $C_{1-6}alkenyl$, $C_{1-6}alkynyl$, carbocyclyl, heterocyclyl, aryl, heteroaryl, $C_{1-6}aralkyl$, and $C_{1-6}heteroaralkyl$;

15 provided that in any occurrence of the sequence ZAZ, at least one member of the sequence must be other than a covalent bond.

In some embodiments, R^5 , R^6 , and R^7 are selected from $C_{1-6}alkyl$ or $C_{1-6}aralkyl$. In preferred embodiments, R^6 is $C_{1-6}alkyl$ and R^5 and R^7 are $C_{1-6}aralkyl$. In the most preferred embodiment, R^6 is isobutyl, R^5 is 2-phenylethyl, and R^7 is phenylmethyl.

20 In certain embodiments, L and Q are absent and R^{11} is selected from $C_{1-6}alkyl$, $C_{1-6}alkenyl$, $C_{1-6}alkynyl$, $C_{1-6}aralkyl$, and $C_{1-6}heteroaralkyl$. In certain such embodiments, R^{10} is $C_{1-6}alkyl$ and R^{11} is selected from butyl, allyl, propargyl, phenylmethyl, 2-pyridyl, 3-pyridyl, and 4-pyridyl.

25 In other embodiments, L is SO_2 , Q is absent, and R^{11} is selected from $C_{1-6}alkyl$ and aryl. In certain such embodiments, R^{11} is selected from methyl and phenyl.

In certain embodiments, L is $C=O$ and R^{11} is selected from $C_{1-6}alkyl$, $C_{1-6}alkenyl$, $C_{1-6}alkynyl$, aryl, $C_{1-6}aralkyl$, heteroaryl, $C_{1-6}heteroaralkyl$, $R^{15}ZA-C_{1-8}alkyl-$, $R^{18}Z-C_{1-8}alkyl-$, $(R^{15}O)(R^{16}O)P(=O)O-C_{1-8}alkyl-$, $(R^{15}O)(R^{16}O)P(=O)O-C_{1-8}alkyl-ZAZ-C_{1-8}alkyl-$, $(R^{15}O)(R^{16}O)P(=O)O-C_{1-8}alkyl-Z-C_{1-8}alkyl-$, $R^{15}ZA-C_{1-8}alkyl-ZAZ-C_{1-8}alkyl-$,
30 heterocyclylMZA-C₁₋₈alkyl-, $(R^{17})_2N-C_{1-8}alkyl-$, $(R^{17})_3N^+-C_{1-8}alkyl-$, heterocyclylM-,

carbocyclylM-, $R^{18}SO_2C_{1-8}alkyl$ -, and $R^{18}SO_2NH$ -, wherein each occurrence of Z and A is independently other than a covalent bond. In certain embodiments, L is C=O, Q is absent, and R^{11} is H.

5 In certain embodiments, R^{10} is $C_{1-6}alkyl$, R^{11} is $C_{1-6}alkyl$, Q is absent, and L is C=O. In certain such embodiments, R^{11} is ethyl, isopropyl, 2,2,2-trifluoroethyl, or 2-(methylsulfonyl)ethyl.

In other embodiments, L is C=O, Q is absent, and R^{11} is $C_{1-6}aralkyl$. In certain such embodiments, R^{11} is selected from 2-phenylethyl, phenylmethyl, (4-methoxyphenyl)methyl, (4-chlorophenyl)methyl, and (4-fluorophenyl)methyl.

10 In other embodiments, L is C=O, Q is absent, R^{10} is $C_{1-6}alkyl$, and R^{11} is aryl. In certain such embodiments, R^{11} is substituted or unsubstituted phenyl.

In certain embodiments, L is C=O, Q is absent or O, n is 0 or 1, and R^{11} is $-(CH_2)_n$ carbocyclyl. In certain such embodiments, R^{11} is cyclopropyl or cyclohexyl.

15 In certain embodiments, L and A are C=O, Q is absent, Z is O, n is an integer from 1 to 8 (preferably 1), and R^{11} is selected from $R^{15}ZA-C_{1-8}alkyl$ -, $R^{18}Z-C_{1-8}alkyl$ -, $R^{15}ZA-C_{1-8}alkyl-ZAZ-C_{1-8}alkyl$ -, $(R^{15}O)(R^{16}O)P(=O)O-C_{1-8}alkyl-ZAZ-C_{1-8}alkyl$ -, $(R^{15}O)(R^{16}O)P(=O)O-C_{1-8}alkyl-Z-C_{1-8}alkyl$ -, and heterocyclylMZA-Z-C₁₋₈alkyl-, wherein each occurrence of A is independently other than a covalent bond. In certain such
20 embodiments, R^7 is heterocyclylMZA-Z-C₁₋₈alkyl- where heterocyclyl is substituted or unsubstituted oxodioxolenyl or $N(R^{12})(R^{13})$, wherein R^{12} and R^{13} together are $C_{1-6}alkyl$ -Y- $C_{1-6}alkyl$, preferably $C_{1-3}alkyl$ -Y- $C_{1-3}alkyl$, thereby forming a ring.


In certain preferred embodiments, L is C=O, Q is absent, n is an integer from 1 to 8, and R^{11} is selected from $(R^{15}O)(R^{16}O)P(=O)O-C_{1-8}alkyl$ -, $(R^{17})_2NC_{1-8}alkyl$, $(R^{17})_3N^+(CH_2)_n$ -, and heterocyclyl-M-. In certain such embodiments, R^{11} is $-C_{1-8}alkylN(R^{17})_2$ or $-C_{1-8}alkylN^+(R^{17})_3$, where R^{17} is $C_{1-6}alkyl$. In certain other such
25 embodiments, R^{11} is heterocyclylM-, where heterocyclyl is selected from morpholino, piperidino, piperazino, and pyrrolidino.

In certain embodiments, L is C=O, R^{10} is $C_{1-6}alkyl$, Q is selected from O and NH and R^{11} is selected from $C_{1-6}alkyl$, cycloalkyl-M, $C_{1-6}aralkyl$, and $C_{1-6}heteroaralkyl$. In
30 other embodiments, L is C=O, R^{10} is $C_{1-6}alkyl$, Q is selected from O and NH, and R^{11} is

C₁₋₆alkyl, where C₁₋₆alkyl is selected from methyl, ethyl, and isopropyl. In further
embodiments, L is C=O, R¹⁰ is C₁₋₆alkyl, Q is selected from O and NH and R¹¹ is C<sub>1-
6</sub>aralkyl, where aralkyl is phenylmethyl. In other embodiments, L is C=O, R¹⁰ is C<sub>1-
6</sub>alkyl, Q is selected from O and NH, and R¹¹ is C₁₋₆heteroaralkyl, where heteroaralkyl is
5 (4-pyridyl)methyl.

In certain embodiments, L is absent or is C=O, and R¹⁰ and R¹¹ together are C<sub>1-
6</sub>alkyl-Y-C₁₋₆alkyl, C₁₋₆alkyl-ZA-C₁₋₆alkyl, or C₁₋₆alkyl-A, wherein each occurrence of Z
and A is independently other than a covalent bond, thereby forming a ring. In certain
preferred embodiments, L is C=O, Q and Y are absent, and R¹⁰ and R¹¹ together are C<sub>1-
10 3</sub>alkyl-Y-C₁₋₃alkyl. In another preferred embodiment, L and Q are absent, and R¹⁰ and
R¹¹ together are C₁₋₃alkyl-Y-C₁₋₃alkyl. In another preferred embodiment, L is C=O, Q is
absent, Y is selected from NH and N-C₁₋₆alkyl, and R¹⁰ and R¹¹ together are C₁₋₃alkyl-Y-
C₁₋₃alkyl. In another preferred embodiment, L is C=O, Y is absent, and R¹⁰ and R¹¹
together are C₁₋₃alkyl-Y-C₁₋₃alkyl. In another preferred embodiment, L and A are C=O,
15 and R¹⁰ and R¹¹ together are C₁₋₂alkyl-ZA-C₁₋₂alkyl. In another preferred embodiment, L
and A are C=O and R¹⁰ and R¹¹ together are C₂₋₃alkyl-A.

In certain embodiments, the chain of amino acids has a structure of formula (VII)



(VII)

20 wherein

each A is independently selected from C=O, C=S, and SO₂, preferably C=O; or

A is optionally a covalent bond when adjacent to an occurrence of Z;

each B is independently selected from C=O, C=S, and SO₂, preferably C=O;

D is absent or is C₁₋₈alkyl;

25 G is selected from O, NH, and N-C₁₋₆alkyl;

K is absent or is selected from C=O, C=S, and SO₂, preferably K is absent or is C=O;

L is absent or is selected from C=O, C=S, and SO₂, preferably L is absent or C=O;

- M is absent or is C₁₋₈alkyl;
- Q is absent or is selected from O, NH, and N-C₁₋₆alkyl, preferably Q is absent, O, or NH, most preferably Q is absent;
- X is COOH or an activated form thereof, preferably X is COOH, COCl, or
- 5 CON(Me)(OMe), most preferably X is COOH or COCl;
- each V is independently absent or is selected from O, S, NH, and N-C₁₋₆alkyl, preferably V is absent or O;
- W is absent or is independently selected from O, S, NH, and N-C₁₋₆alkyl, preferably O;
- Y is absent or is selected from O, NH, N-C₁₋₆alkyl, S, SO, SO₂, CHOR¹⁷, and CHCO₂R¹⁷;
- 10 each Z is independently selected from O, S, NH, and N-C₁₋₆alkyl, preferably O; or
- Z is optionally a covalent bond when adjacent to an occurrence of A;
- R⁵, R⁶, and R⁷ are each independently selected from C₁₋₆alkyl, C₁₋₆hydroxyalkyl, C₁₋₆alkoxyalkyl, aryl, C₁₋₆aralkyl, and R¹⁶DVKOC₁₋₃alkyl-, wherein at least one of R⁵ and R⁷ is R¹⁶DVKOC₁₋₃alkyl-;
- 15 R⁹ is N(R¹⁰)LQR¹¹;
- R¹⁰ is selected from hydrogen, OH, and C₁₋₆alkyl, preferably hydrogen or C₁₋₆alkyl;
- R¹¹ is a further chain of amino acids, hydrogen, a protecting group, aryl, or heteroaryl, any of which is optionally substituted with halogen, carbonyl, nitro, hydroxy, aryl, C₁₋₅alkyl; or R¹¹ is selected from C₁₋₆alkyl, C₁₋₆alkenyl, C₁₋₆alkynyl, C₁₋₆aralkyl,
- 20 C₁₋₆heteroaralkyl, R¹²ZAZ-C₁₋₈alkyl-, R¹⁵ZAZ-C₁₋₈alkyl-, (R¹²O)(R¹³O)P(=O)O-C₁₋₈alkyl-ZAZ-C₁₋₈alkyl-, R¹²ZAZ-C₁₋₈alkyl-ZAZ-C₁₋₈alkyl-, heterocycliM-ZAZ-C₁₋₈alkyl-, (R¹²O)(R¹³O)P(=O)O-C₁₋₈alkyl-, (R¹⁴)₂N-C₁₋₈alkyl-, (R¹⁴)₃N⁺-C₁₋₈alkyl-, heterocycliM-, carbocycliM-, R¹⁵SO₂C₁₋₈alkyl-, and R¹⁵SO₂NH; or
- R¹⁰ and R¹¹ together are C₁₋₆alkyl-Y-C₁₋₆alkyl, C₁₋₆alkyl-ZAZ-C₁₋₆alkyl, ZAZ-C₁₋₆alkyl-
- 25 ZAZ-C₁₋₆alkyl, ZAZ-C₁₋₆alkyl-ZAZ, or C₁₋₆alkyl-ZAZ;
- R¹² and R¹³ are independently selected from hydrogen, metal cation, C₁₋₆alkyl, C₁₋₆alkenyl, C₁₋₆alkynyl, aryl, heteroaryl, C₁₋₆aralkyl, and C₁₋₆heteroaralkyl, preferably from hydrogen, metal cation, and C₁₋₆alkyl, or R¹² and R¹³ together are C₁₋₆alkyl, thereby forming a ring;

each R¹⁴ is independently selected from hydrogen and C₁₋₆alkyl, preferably C₁₋₆alkyl;

each R¹⁵ is independently selected from hydrogen, OR¹⁴, C₁₋₆alkyl, C₁₋₆alkenyl, C₁₋₆alkynyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, C₁₋₆aralkyl, and C₁₋₆heteroaralkyl;

5 R¹⁶ is selected from hydrogen, (R¹⁷O)(R¹⁸O)P(=O)W-, R¹⁷GB-, heterocyclyl-, (R¹⁹)₂N-, (R¹⁹)₃N⁺-, R¹⁹SO₂GBG-, and R¹⁷GBC₁₋₈alkyl- where the C₁₋₈alkyl moiety is optionally substituted with OH, C₁₋₈alkylW (optionally substituted with halogen, preferably fluorine), aryl, heteroaryl, carbocyclyl, heterocyclyl, and C₁₋₆aralkyl, preferably at least one occurrence of R¹⁶ is other than hydrogen;

10 R¹⁷ and R¹⁸ are independently selected from hydrogen, metal cation, C₁₋₆alkyl, C₁₋₆alkenyl, C₁₋₆alkynyl, aryl, heteroaryl, C₁₋₆aralkyl, and C₁₋₆heteroaralkyl, preferably from hydrogen, metal cation, and C₁₋₆alkyl, or R¹⁷ and R¹⁸ together are C₁₋₆alkyl, thereby forming a ring; and

each R¹⁹ is independently selected from hydrogen, OR¹⁴, C₁₋₆alkyl, C₁₋₆alkenyl, C₁₋

15 ₆alkynyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, C₁₋₆aralkyl, and C₁₋₆heteroaralkyl; and

D, G, V, K, and W are selected such that there are no O-O, N-O, S-N, or S-O bonds.

In certain embodiments, R⁵, R⁶, and R⁷ are each independently selected from C₁₋₆alkyl, C₁₋₆hydroxyalkyl, C₁₋₆alkoxyalkyl, aryl, C₁₋₆aralkyl, and R¹⁶DVKOC₁₋₃alkyl-
20 wherein at least one of R⁵ and R⁷ is R¹⁶DVKOC₁₋₃alkyl-. In preferred embodiments, one of R⁵ and R⁷ is C₁₋₆aralkyl and the other is R¹⁶DVKOC₁₋₃alkyl-, and R⁶ is independently C₁₋₆alkyl. In the most preferred embodiment, one of R⁵ and R⁷ is 2-phenylethyl or phenylmethyl and the other is R¹⁶DVKOCH₂- or R¹⁶DVKO(CH₃)CH-, and R⁶ is isobutyl.

In certain embodiments, each R¹⁵ is independently selected from hydrogen, C₁₋
25 ₆alkyl, C₁₋₆alkenyl, C₁₋₆alkynyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, C₁₋₆aralkyl, and C₁₋₆heteroaralkyl.

In certain embodiments, each R¹⁹ is independently selected from hydrogen, C₁₋
₆alkyl, C₁₋₆alkenyl, C₁₋₆alkynyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, C₁₋₆aralkyl, and C₁₋₆heteroaralkyl.

In certain embodiments, L and Q are absent and R^{11} is selected from hydrogen, a further chain of amino acids, C_{1-6} acyl, a protecting group, aryl, heteroaryl, C_{1-6} alkyl, C_{1-6} alkenyl, C_{1-6} alkynyl, C_{1-6} aralkyl, and C_{1-6} heteroaralkyl. In certain such embodiments, R^{10} is C_{1-6} alkyl and R^{11} is selected from butyl, allyl, propargyl, phenylmethyl, 2-pyridyl, 3-pyridyl, and 4-pyridyl.

In other embodiments, L is SO_2 , Q is absent, and R^{11} is selected from C_{1-6} alkyl and aryl. In certain such embodiments, R^{11} is selected from methyl and phenyl.

In certain embodiments, L is $C=O$ and R^{11} is selected from C_{1-6} alkyl, C_{1-6} alkenyl, C_{1-6} alkynyl, aryl, C_{1-6} aralkyl, heteroaryl, C_{1-6} heteroaralkyl, $R^{12}ZA-C_{1-8}$ alkyl-, $R^{15}Z-C_{1-8}$ alkyl-, $(R^{12}O)(R^{13}O)P(=O)O-C_{1-8}$ alkyl-, $(R^{12}O)(R^{13}O)P(=O)O-C_{1-8}$ alkyl-ZAZ- C_{1-8} alkyl-, $(R^{12}O)(R^{13}O)P(=O)O-C_{1-8}$ alkyl-Z- C_{1-8} alkyl-, $R^{12}ZA-C_{1-8}$ alkyl-ZAZ- C_{1-8} alkyl-, heterocyclylMZAZ- C_{1-8} alkyl-, $(R^{14})_2N-C_{1-8}$ alkyl-, $(R^{14})_3N^+-C_{1-8}$ alkyl-, heterocyclylM-, carbocyclylM-, $R^{15}SO_2C_{1-8}$ alkyl-, and $R^{15}SO_2NH-$. In certain embodiments, L is $C=O$, Q is absent, and R^{11} is H.

In certain embodiments, R^{10} is C_{1-6} alkyl, R^{11} is C_{1-6} alkyl, Q is absent, and L is $C=O$. In certain such embodiments, R^{11} is ethyl, isopropyl, 2,2,2-trifluoroethyl, or 2-(methylsulfonyl)ethyl.

In other embodiments, L is $C=O$, Q is absent, and R^{11} is C_{1-6} aralkyl. In certain such embodiments, R^{11} is selected from 2-phenylethyl, phenylmethyl, (4-methoxyphenyl)methyl, (4-chlorophenyl)methyl, and (4-fluorophenyl)methyl.

In other embodiments, L is $C=O$, Q is absent, R^{10} is C_{1-6} alkyl, and R^{11} is aryl. In certain such embodiments, R^{11} is substituted or unsubstituted phenyl.

In certain embodiments, L is $C=O$, Q is absent or O, and R^{11} is $-(CH_2)_n$ carbocyclyl. In certain such embodiments, R^{11} is cyclopropyl or cyclohexyl.

In certain embodiments, L and A are $C=O$, Q is absent, Z is O, and R^{11} is selected from $R^{12}ZA-C_{1-8}$ alkyl-, $R^{15}Z-C_{1-8}$ alkyl-, $R^{12}ZA-C_{1-8}$ alkyl-ZAZ- C_{1-8} alkyl-, $(R^{12}O)(R^{13}O)P(=O)O-C_{1-8}$ alkyl-ZAZ- C_{1-8} alkyl-, $(R^{12}O)(R^{13}O)P(=O)O-C_{1-8}$ alkyl-Z- C_{1-8} alkyl-, and heterocyclylMZAZ- C_{1-8} alkyl-. In certain such embodiments, R^{11} is heterocyclylMZAZ- C_{1-8} alkyl- where heterocyclyl is substituted or unsubstituted

oxodioxolenyl or $N(R^{20})(R^{21})$, wherein R^{20} and R^{21} together are C_{1-6} alkyl-Y- C_{1-6} alkyl, preferably C_{1-3} alkyl-Y- C_{1-3} alkyl, thereby forming a ring.

In certain preferred embodiments, L is C=O, Q is absent, and R^{11} is selected from $(R^{12}O)(R^{13}O)P(=O)O-C_{1-8}$ alkyl-, $(R^{14})_2NC_{1-8}$ alkyl, $(R^{14})_3N^+(CH_2)_n$ -, and heterocyclyl-M-.

5 In certain such embodiments, R^{11} is $-C_{1-8}$ alkylN(R^{14})₂ or $-C_{1-8}$ alkylN⁺(R^{14})₃, where R^{14} is C_{1-6} alkyl. In certain other such embodiments, R^{11} is heterocyclylM-, where heterocyclyl is selected from morpholino, piperidino, piperazino, and pyrrolidino.

In certain embodiments, L is C=O, R^{10} is C_{1-6} alkyl, Q is selected from O and NH and R^{11} is selected from C_{1-6} alkyl, cycloalkyl-M, C_{1-6} araalkyl, and C_{1-6} heteroaraalkyl. In
10 other embodiments, L is C=O, R^{10} is C_{1-6} alkyl, Q is selected from O and NH, and R^{11} is C_{1-6} alkyl, where C_{1-6} alkyl is selected from methyl, ethyl, and isopropyl. In further embodiments, L is C=O, R^{10} is C_{1-6} alkyl, Q is selected from O and NH and R^{11} is C_{1-6} aralkyl, where aralkyl is phenylmethyl. In other embodiments, L is C=O, R^{10} is C_{1-6} alkyl, Q is selected from O and NH, and R^{11} is C_{1-6} heteroaralkyl, where heteroaralkyl is
15 (4-pyridyl)methyl.

In certain embodiments, L is absent or is C=O, and R^{10} and R^{11} together are C_{1-6} alkyl-Y- C_{1-6} alkyl, C_{1-6} alkyl-ZA- C_{1-6} alkyl, or C_{1-6} alkyl-A, thereby forming a ring. In certain preferred embodiments, L is C=O, Q and Y are absent, and R^{10} and R^{11} together are C_{1-3} alkyl-Y- C_{1-3} alkyl. In another preferred embodiment, L and Q are absent, and R^{10}
20 and R^{11} together are C_{1-3} alkyl-Y- C_{1-3} alkyl. In another preferred embodiment, L is C=O, Q is absent, Y is selected from NH and N- C_{1-6} alkyl, and R^{10} and R^{11} together are C_{1-3} alkyl-Y- C_{1-3} alkyl. In another preferred embodiment, L is C=O, Y is absent, and R^{10} and R^{11} together are C_{1-3} alkyl-Y- C_{1-3} alkyl. In another preferred embodiment, L and A are C=O, and R^{10} and R^{11} together are C_{1-2} alkyl-ZA- C_{1-2} alkyl. In another preferred
25 embodiment, L and A are C=O and R^{10} and R^{11} together are C_{2-3} alkyl-A.

In certain embodiments, R^{16} is $(R^{17}O)(R^{18}O)P(=O)W$ -. In certain such embodiments, D, V, K, and W are absent. In other such embodiments, V and K are absent, D is C_{1-8} alkyl, and W is O. In yet other such embodiments, D is C_{1-8} alkyl, K is C=O, and V and W are O.

30 In certain embodiments, R^{16} is $R^{17}GB$ -. In preferred embodiments, B is C=O, G is O, D is C_{1-8} alkyl, V is O, and K is C=O.


In certain embodiments, R^{16} is heterocyclyl-. In preferred such embodiments, D is C_{1-8} alkyl. In certain such embodiments, V is O, K is C=O, and heterocyclyl is oxodioxolenyl. In other such embodiments, V is absent, K is absent or is C=O, and heterocyclyl is $N(R^{20})(R^{21})$, where R^{20} and R^{21} together are J-T-J, J-WB-J, or B-J-T-J, T is absent or is selected from O, NR^{17} , S, SO, SO_2 , $CHOR^{19}$, $CHCO_2R^{17}$, C=O, CF_2 , and CHF, and J is absent or is C_{1-3} alkyl.

In certain embodiments, R^{16} is $(R^{19})_2N^-$ or $(R^{19})_3N^+$ -, and preferably V is absent. In preferred such embodiments, D is C_{1-8} alkyl and K is absent or C=O. In certain embodiments where V is absent and R^{16} is $(R^{19})_2N^-$, D is absent K is absent or is C=O, preferably K is C=O.

In certain embodiments, R^{16} is $R^{19}SO_2GBG^-$. In preferred such embodiments, B is C=O, D, V, and K are absent, and G is NH or NC_{1-6} alkyl.

In certain embodiments, R^{16} is $R^{17}GBC_{1-8}$ alkyl-. In preferred embodiments, B is C=O, G is O, and the C_{1-8} alkyl moiety is optionally substituted with OH, C_{1-8} alkyl (optionally substituted with halogen, preferably fluorine), C_{1-8} alkylW, aryl, heteroaryl, carbocyclyl, heterocyclyl, and C_{1-6} aralkyl. In certain such embodiments, the C_{1-8} alkyl moiety is an unsubstituted, mono-, or disubstituted C_1 alkyl.

In certain embodiments, the chain of amino acids has a structure of formula (VIII) or (IX) or a pharmaceutically acceptable salt thereof



wherein

each Ar is independently an aromatic or heteroaromatic group optionally substituted with 1 to 4 substituents;

L is absent or is selected from C=O, C=S, and SO_2 , preferably SO_2 or C=O;

X is COOH or an activated form thereof, preferably X is COOH, COCl, or $CON(Me)(OMe)$, most preferably X is COOH or COCl;

Y is absent or is selected from C=O and SO_2 ;

Z is absent or is C₁₋₆alkyl;

R⁵ and R⁶ are each independently selected from C₁₋₆alkyl, C₁₋₆hydroxyalkyl, C₁₋₆alkoxyalkyl, aryl, and C₁₋₆aralkyl, any of which is optionally substituted with one or more of amide, amine, carboxylic acid (or a salt thereof), ester (including C₁₋₆alkyl ester, C₁₋₅alkyl ester, and aryl ester), thiol, or thioether substituents;

R⁹ is N(R¹⁰)L-Z-R¹¹;

R¹⁰ is selected from hydrogen, OH, C₁₋₆aralkyl-Y-, and C₁₋₆alkyl-Y-, preferably hydrogen;

R¹¹ is selected from hydrogen, OR¹², C₁₋₆alkenyl, Ar-Y-, carbocyclyl, and heterocyclyl; and

R¹² is selected from hydrogen, C₁₋₆alkyl, and C₁₋₆aralkyl, preferably hydrogen.

In certain embodiments, L is selected from C=O, C=S, and SO₂, preferably SO₂ or C=O.

In certain embodiments, R¹⁰ is selected from hydrogen, OH, C₁₋₆aralkyl, and C₁₋₆alkyl, preferably hydrogen.

In certain embodiments, R¹¹ is selected from hydrogen, C₁₋₆alkenyl, Ar-Y-, carbocyclyl, and heterocyclyl.

In certain embodiments, R⁵ and R⁶ are each independently selected from C₁₋₆alkyl, C₁₋₆hydroxyalkyl, and C₁₋₆aralkyl. In preferred such embodiments, R⁵ is C₁₋₆alkyl and R⁶ is C₁₋₆aralkyl. In more preferred such embodiments, R⁵ is isobutyl and R⁶ is phenylmethyl.

In certain embodiments, R¹⁰ is hydrogen, L is C=O or SO₂, R¹¹ is Ar-Y-, and each Ar is independently selected from phenyl, indolyl, benzofuranyl, naphthyl, quinolinyl, quinolonyl, thienyl, pyridyl, pyrazyl, and the like. In certain such embodiments, Ar may be substituted with Ar-Q-, where Q is selected from a direct bond, -O-, and C₁₋₆alkyl. In certain other such embodiments where Z is C₁₋₆alkyl, Z may be substituted, preferably with Ar, e.g., phenyl.


In certain embodiments, R¹⁰ is hydrogen, Z is absent, L is C=O or SO₂, and R¹¹ is selected from Ar-Y and heterocyclyl. In certain preferred such embodiments,

heterocyclyl is selected from chromonyl, chromanyl, morpholino, and piperidinyl. In certain other preferred such embodiments, Ar is selected from phenyl, indolyl, benzofuranyl, naphthyl, quinolinyl, quinolonyl, thienyl, pyridyl, pyrazyl, and the like.

5 In certain embodiments, R¹⁰ is hydrogen, L is C=O or SO₂, Z is absent, and R¹¹ is C₁₋₆alkenyl, where C₁₋₆alkenyl is a substituted vinyl group where the substituent is preferably an aryl or heteroaryl group, more preferably a phenyl group optionally substituted with one to four substituents.

10 In certain embodiments, R¹² is selected from hydrogen and C₁₋₆alkyl. In certain preferred such embodiments, R¹² is selected from hydrogen and methyl. In more preferred such embodiments, R¹² is hydrogen.

In certain preferred embodiments, the chain of amino acids has a structure of formula (X)




(X)

15 X is COOH or an activated form thereof, preferably X is COOH, COCl, or CON(Me)(OMe), most preferably X is COOH or COCl;

20 R⁵, R⁶, and R⁷ are independently selected from C₁₋₆alkyl, C₁₋₆hydroxyalkyl, C₁₋₆alkoxyalkyl, aryl, and C₁₋₆aralkyl, each of which is optionally substituted with a group selected from amide, amine, carboxylic acid or a pharmaceutically acceptable salt thereof, carboxyl ester, thiol, and thioether, preferably R⁶ is C₁₋₆alkyl and R⁵ and R⁷ are C₁₋₆aralkyl, most preferably, R⁶ is isobutyl, R⁵ is 2-phenylethyl, and R⁷ is phenylmethyl;

R⁹ is a further chain of amino acids, hydrogen, C₁₋₆acyl, a protecting group, aryl, or heteroaryl, where substituents include halogen, carbonyl, nitro, hydroxy, aryl, and C₁₋₅alkyl, preferably R⁹ is C₁₋₆acyl, most preferably R⁹ is acetyl.

25 In certain preferred embodiments, the chain of amino acids has a structure of formula (XI) or a pharmaceutically acceptable salt thereof,



(XI)

wherein


L is absent or is selected from $-\text{CO}_2$ or $-\text{C}(=\text{S})\text{O}$;

5 X is COOH or an activated form thereof, preferably X is COOH , COCl , or $\text{CON}(\text{Me})(\text{OMe})$, most preferably X is COOH or COCl ;

Y is NH , N-alkyl, O, or $\text{C}(\text{R}^9)_2$, preferably N-alkyl, O, or $\text{C}(\text{R}^9)_2$;

Z is O or $\text{C}(\text{R}^9)_2$, preferably $\text{C}(\text{R}^9)_2$;

10 R^1 , R^2 , and R^3 are independently selected from hydrogen and a group of formula (XII), preferably, R^1 , R^2 , and R^3 are all the same, more preferably R^1 , R^2 , and R^3 are all hydrogen;



(XII)

15 each R^5 , R^6 , R^7 , and R^9 is independently selected from hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} alkoxyalkyl, aryl, and C_{1-6} aralkyl, each of which is optionally substituted with a group selected from alkyl, amide, amine, carboxylic acid or a pharmaceutically acceptable salt thereof, carboxyl ester, thiol, and thioether, preferably R^5 , R^6 , and R^7 are independently selected from C_{1-6} alkyl, C_{1-6} hydroxyalkyl, and C_{1-6} aralkyl and each R^9 is hydrogen, more preferably, R^6 is C_{1-6} alkyl, R^5 and R^7 are
20 independently C_{1-6} aralkyl and each R^9 is H;

R^{10} and R^{11} are independently selected from hydrogen and C_{1-6} alkyl, or R^{10} and R^{11} together form a 3- to 6-membered carbocyclic or heterocyclic ring;

R^{12} and R^{13} are independently selected from hydrogen, a metal cation, C_{1-6} alkyl, and C_{1-6} aralkyl, or R^{12} and R^{13} together represent C_{1-6} alkyl, thereby forming a ring;

25 m is an integer from 0 to 2; and

n is an integer from 0 to 2, preferably 0 or 1.


In certain embodiments, X is O and R¹, R², and R³ are all the same, preferably R¹, R², and R³ are all hydrogen. In certain such embodiments, R⁵, R⁶, and R⁷ are independently selected from C₁₋₆alkyl, C₁₋₆hydroxyalkyl, and C₁₋₆aralkyl, more preferably, R⁶ is C₁₋₆alkyl and R⁵ and R⁷ are independently C₁₋₆aralkyl.

In certain preferred embodiments, R¹, R², and R³ are all hydrogen, R⁶ and R⁸ are both isobutyl, R⁵ is phenylethyl, and R⁷ is phenylmethyl.

In certain embodiments, R⁵, R⁶, and R⁷ are independently selected from hydrogen, C₁₋₆alkyl, C₁₋₆hydroxyalkyl, C₁₋₆alkoxyalkyl, aryl, and C₁₋₆aralkyl, each of which is optionally substituted with a group selected from alkyl, amide, amine, carboxylic acid or a pharmaceutically acceptable salt thereof, carboxyl ester, thiol, and thioether. In certain embodiments, at least one of R⁵ and R⁷ is C₁₋₆aralkyl substituted with alkyl, more preferably substituted with perhaloalkyl. In certain such embodiments, R⁷ is C₁₋₆aralkyl substituted with trifluoromethyl.

In certain embodiments, Y is selected from N-alkyl, O, and CH₂. In certain such embodiments, Z is CH₂, and m and n are both 0. In certain alternative such embodiments, Z is CH₂, m is 0, and n is 2 or 3. In yet another alternative such embodiments, Z is O, m is 1, and n is 2.

In certain preferred embodiments, the chain of amino acids has a structure of formula (XIII)



(XIII)

wherein

each Ar is independently an aromatic or heteroaromatic group optionally substituted with 1 to 4 substituents;

each A is independently selected from C=O, C=S, and SO₂, preferably C=O; or

A is optionally a covalent bond when adjacent to an occurrence of Z;

- B is absent or is $N(R^9)R^{10}$, preferably absent;
- L is absent or is selected from C=O, C=S, and SO₂, preferably SO₂ or C=O;
- M is absent or is C₁₋₁₂alkyl, preferably C₁₋₈alkyl;
- Q is absent or is selected from O, NH, and N-C₁₋₆alkyl;
- 5 X is COOH or an activated form thereof, preferably X is COOH, COCl, or CON(Me)(OMe), most preferably X is COOH or COCl;
- Y is absent or is selected from C=O and SO₂;
- each Z is independently selected from O, S, NH, and N-C₁₋₆alkyl, preferably O; or
- Z is optionally a covalent bond when adjacent to an occurrence of A;
- 10 R¹ is selected from H, -C₁₋₆alkyl-B, C₁₋₆hydroxyalkyl, C₁₋₆alkoxyalkyl, aryl, and C₁₋₆aralkyl;
- R² is selected from aryl, C₁₋₆aralkyl, heteroaryl, and C₁₋₆heteroaralkyl;
- R⁴ is $N(R^5)L-Q-R^6$;
- R⁵ is selected from hydrogen, OH, C₁₋₆aralkyl, and C₁₋₆alkyl, preferably hydrogen;
- 15 R⁶ is selected from hydrogen, C₁₋₆alkyl, C₁₋₆alkenyl, C₁₋₆alkynyl, Ar-Y-, carbocyclyl, heterocyclyl, an N-terminal protecting group, aryl, C₁₋₆aralkyl, heteroaryl, C₁₋₆heteroaralkyl, R¹¹ZAZ-C₁₋₈alkyl-, R¹⁴Z-C₁₋₈alkyl-, (R¹¹O)(R¹²O)P(=O)O-C₁₋₈alkyl-ZAZ-C₁₋₈alkyl-, R¹¹ZAZ-C₁₋₈alkyl-ZAZ-C₁₋₈alkyl-, heterocyclylMZAZ-C₁₋₈alkyl-, (R¹¹O)(R¹²O)P(=O)O-C₁₋₈alkyl-, (R¹³)₂N-C₁₋₁₂alkyl-, (R¹³)₃N⁺-C₁₋₁₂alkyl-,
- 20 heterocyclylM-, carbocyclylM-, R¹⁴SO₂C₁₋₈alkyl-, and R¹⁴SO₂NH; preferably an N-capping group, more preferably t-butoxycarbonyl or benzyloxycarbonyl; or
- R⁵ and R⁶ together are C₁₋₆alkyl-Y-C₁₋₆alkyl, C₁₋₆alkyl-ZAZ-C₁₋₆alkyl, ZAZ-C₁₋₆alkyl-ZAZ-C₁₋₆alkyl, ZAZ-C₁₋₆alkyl-ZAZ, or C₁₋₆alkyl-A, thereby forming a ring;
- R⁷ is selected from hydrogen, C₁₋₆alkyl, and C₁₋₆aralkyl, preferably hydrogen;
- 25 R⁹ is selected from hydrogen, OH, and C₁₋₆alkyl, preferably C₁₋₆alkyl; and
- R¹⁰ is an N-terminal protecting group;
- R¹¹ and R¹² are independently selected from hydrogen, metal cation, C₁₋₆alkyl, C₁₋₆alkenyl, C₁₋₆alkynyl, aryl, heteroaryl, C₁₋₆aralkyl, and C₁₋₆heteroaralkyl, preferably from

hydrogen, metal cation, and C₁₋₆alkyl, or R¹¹ and R¹² together are C₁₋₆alkyl, thereby forming a ring;


each R¹³ is independently selected from hydrogen and C₁₋₆alkyl, preferably C₁₋₆alkyl; and

5 R¹⁴ is independently selected from hydrogen, C₁₋₆alkyl, C₁₋₆alkenyl, C₁₋₆alkynyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, C₁₋₆aralkyl, and C₁₋₆heteroaralkyl;

provided that in any occurrence of the sequence ZAZ, at least one member of the sequence must be other than a covalent bond.

10 In certain embodiments, R¹ is selected from -C₁₋₆alkyl-B and C₁₋₆aralkyl. In certain such embodiments, R¹ is substituted with one or more substituents selected from hydroxy, halogen, amide, amine, carboxylic acid (or a salt thereof), ester (including C₁₋₆alkyl ester, C₁₋₅alkyl ester, and aryl ester), thiol, or thioether. In certain preferred such embodiments, R¹ is substituted with one or more substituents selected from carboxylic acid and ester. In certain embodiments, R¹ is selected from methyl, ethyl, isopropyl, 15 carboxymethyl, and benzyl. In certain embodiments R¹ is -C₁₋₆alkyl-B and C₁₋₆aralkyl. In certain preferred such embodiments, B is absent.

20 In certain embodiments, R² is selected from C₁₋₆aralkyl and C₁₋₆heteroaralkyl. In certain such embodiments, R² is selected from C₁₋₆alkyl-phenyl, C₁₋₆alkyl-indolyl, C₁₋₆alkyl-thienyl, C₁₋₆alkyl-thiazolyl, and C₁₋₆alkyl-isothiazolyl, wherein the alkyl moiety may contain six, five, four, three, two, or one carbon atoms, preferably one or two. In certain such embodiments, R² is substituted with one or more substituents selected from hydroxy, halogen, amide, amine, carboxylic acid (or a salt thereof), ester (including C₁₋₆alkyl ester, C₁₋₅alkyl ester, and aryl ester), thiol, or thioether. In certain such 25 embodiments, R² is substituted with a substituent selected from alkyl, trihaloalkyl, alkoxy, hydroxy, or cyano. In certain such embodiments, R² is selected from C₁₋₆alkyl-phenyl and C₁₋₆alkyl-indolyl. In certain preferred such embodiments, R² is selected from



R = H or any suitable protecting group

wherein D is selected from H, OMe, OMe^t, OH, CN, CF₃ and CH₃. In certain embodiments D is selected from H, OMe, OH, CN, CF₃ and CH₃.

In certain preferred such embodiments where D is attached to a six-membered ring, D is attached at the 4-position relative to the point of attachment, preferably excluding embodiments where the 4-position of the ring is occupied by the nitrogen of a pyridine ring.

In certain embodiments, R⁵ is hydrogen, L is C=O or SO₂, R⁶ is Ar-Y-, and each Ar is independently selected from phenyl, indolyl, benzofuranyl, naphthyl, quinolinyl, quinolonyl, thienyl, pyridyl, pyrazyl, and the like. In certain such embodiments, Ar may be substituted with Ar-E-, where E is selected from a direct bond, -O-, and C₁₋₆alkyl. In certain other such embodiments where Q is C₁₋₆alkyl, Q may be substituted, preferably with Ar, e.g., phenyl.

In certain embodiments, R⁵ is hydrogen, Q is absent, L is C=O or SO₂, and R⁶ is selected from Ar-Y and heterocyclyl. In certain preferred such embodiments, heterocyclyl is selected from chromonyl, chromanyl, morpholino, and piperidinyl. In certain other preferred such embodiments, Ar is selected from phenyl, indolyl, benzofuranyl, naphthyl, quinolinyl, quinolonyl, thienyl, pyridyl, pyrazyl, and the like.

In certain embodiments, R⁵ is hydrogen, L is C=O or SO₂, Q is absent, and R⁶ is C₁₋₆alkenyl, where C₁₋₆alkenyl is a substituted vinyl group where the substituent is preferably an aryl or heteroaryl group, more preferably a phenyl group optionally substituted with one to four substituents.

In certain embodiments, L and Q are absent and R⁶ is selected from C₁₋₆alkyl, C₁₋₆alkenyl, C₁₋₆alkynyl, C₁₋₆aralkyl, and C₁₋₆heteroaralkyl. In certain such embodiments, R⁵ is C₁₋₆alkyl and R⁶ is selected from butyl, allyl, propargyl, phenylmethyl, 2-pyridyl, 3-pyridyl, and 4-pyridyl.

5 In other embodiments, L is SO₂, Q is absent, and R⁶ is selected from C₁₋₆alkyl and aryl. In certain such embodiments, R⁶ is selected from methyl and phenyl.

In certain embodiments, L is C=O and R⁶ is selected from C₁₋₆alkyl, C₁₋₆alkenyl, C₁₋₆alkynyl, aryl, C₁₋₆aralkyl, heteroaryl, C₁₋₆heteroaralkyl, R¹¹ZA-C₁₋₈alkyl-, R¹⁴Z-C₁₋₈alkyl-, (R¹¹O)(R¹²O)P(=O)O-C₁₋₈alkyl-, (R¹¹O)(R¹²O)P(=O)O-C₁₋₈alkyl-ZAZ-C₁₋₈alkyl-, (R¹¹O)(R¹²O)P(=O)O-C₁₋₈alkyl-Z-C₁₋₈alkyl-, R¹¹ZA-C₁₋₈alkyl-ZAZ-C₁₋₈alkyl-, heterocyclylMZAZ-C₁₋₈alkyl-, (R¹³)₂N-C₁₋₈alkyl-, (R¹³)₃N⁺-C₁₋₈alkyl-, heterocyclylM-, carbocyclylM-, R¹⁴SO₂C₁₋₈alkyl-, and R¹⁴SO₂NH-, wherein each occurrence of Z and A is independently other than a covalent bond. In certain embodiments, L is C=O, Q is absent, and R⁶ is H.

10

15 In certain embodiments, R⁵ is C₁₋₆alkyl, R⁶ is C₁₋₆alkyl, Q is absent, and L is C=O. In certain such embodiments, R⁶ is ethyl, isopropyl, 2,2,2-trifluoroethyl, or 2-(methylsulfonyl)ethyl.

In other embodiments, L is C=O, Q is absent, and R⁶ is C₁₋₆aralkyl. In certain such embodiments, R⁶ is selected from 2-phenylethyl, phenylmethyl, (4-methoxyphenyl)methyl, (4-chlorophenyl)methyl, and (4-fluorophenyl)methyl.

20

In other embodiments, L is C=O, Q is absent, R⁵ is C₁₋₆alkyl, and R⁶ is aryl. In certain such embodiments, R⁶ is substituted or unsubstituted phenyl.

In certain embodiments, L is C=O, Q is absent, and R⁶ is selected from heteroaryl and C₁₋₆heteroaralkyl. In certain such embodiments, R⁶ is heteroaryl selected from pyrrole, furan, thiophene, imidazole, isoxazole, oxazole, oxadiazole, thiazole, thiadiazole, triazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine. In certain alternative such embodiments, R⁶ is C₁₋₆heteroaralkyl selected from pyrrolylmethyl, furanylmethyl, thienylmethyl, imidazolylmethyl, isoxazolylmethyl, oxazolylmethyl, oxadiazolylmethyl, thiazolylmethyl, thiadiazolylmethyl, triazolylmethyl, pyrazolylmethyl, pyridylmethyl, pyrazinylmethyl, pyridazinylmethyl and pyrimidinylmethyl.

25

30

In certain embodiments, L is C=O, Q is absent or O, and R⁶ is carbocyclylM-, wherein M is C₀₋₁alkyl. In certain such embodiments, R⁶ is cyclopropyl or cyclohexyl.

In certain embodiments, L and A are C=O, Q is absent, Z is O, M is C₁₋₈alkyl, preferably methylene, and R⁶ is selected from R¹¹ZA-C₁₋₈alkyl-, R¹⁴Z-C₁₋₈alkyl-, R¹¹ZA-C₁₋₈alkyl-ZAZ-C₁₋₈alkyl-, (R¹¹O)(R¹²O)P(=O)O-C₁₋₈alkyl-ZAZ-C₁₋₈alkyl-,
5 (R¹¹O)(R¹²O)P(=O)O-C₁₋₈alkyl-Z-C₁₋₈alkyl-, and heterocyclylMZA-C₁₋₈alkyl-, wherein each occurrence of A is independently other than a covalent bond. In certain such embodiments, R⁶ is heterocyclylMZA-C₁₋₈alkyl- where heterocyclyl is substituted or unsubstituted oxodioxolenyl or N(R¹⁶)(R¹⁷), wherein R¹⁶ and R¹⁷ together are C₁₋₆alkyl-
10 Y-C₁₋₆alkyl, preferably C₁₋₃alkyl-Y-C₁₋₃alkyl, thereby forming a ring.

In certain preferred embodiments, L is C=O, Q is absent, M is C₁₋₈alkyl, and R⁶ is selected from (R¹¹O)(R¹²O)P(=O)O-C₁₋₈alkyl-, (R¹³)₂NC₁₋₈alkyl-, (R¹³)₃N⁺C₁₋₈alkyl-, and heterocyclyl-M-. In certain such embodiments, R⁶ is (R¹³)₂NC₁₋₈alkyl or (R¹³)₃N⁺C₁₋₈alkyl-, where R¹³ is C₁₋₆alkyl. In certain other such embodiments, R⁶ is heterocyclylM-,
15 where heterocyclyl is selected from morpholino, piperidino, piperazino, and pyrrolidino.

In certain embodiments, L is C=O, R⁵ is C₁₋₆alkyl, Q is selected from O and NH and R⁶ is selected from C₁₋₆alkyl, cycloalkyl-M, C₁₋₆aralkyl, and C₁₋₆heteroaralkyl. In other embodiments, L is C=O, R⁵ is C₁₋₆alkyl, Q is selected from O and NH, and R⁶ is C₁₋₆alkyl, where C₁₋₆alkyl is selected from methyl, ethyl, and isopropyl. In further
20 embodiments, L is C=O, R⁵ is C₁₋₆alkyl, Q is selected from O and NH and R⁶ is C₁₋₆aralkyl, where aralkyl is phenylmethyl. In other embodiments, L is C=O, R⁵ is C₁₋₆alkyl, Q is selected from O and NH, and R⁶ is C₁₋₆heteroaralkyl, where heteroaralkyl is (4-pyridyl)methyl.


In certain embodiments, L is absent or is C=O, and R⁵ and R⁶ together are C₁₋₆alkyl-Y-C₁₋₆alkyl, C₁₋₆alkyl-ZA-C₁₋₆alkyl, or C₁₋₆alkyl-A, wherein each occurrence of Z and A is independently other than a covalent bond, thereby forming a ring. In certain preferred embodiments, L is C=O, Q and Y are absent, and R⁵ and R⁶ together are C₁₋₃alkyl-Y-C₁₋₃alkyl. In another preferred embodiment, L and Q are absent, and R⁵ and R⁶ together are C₁₋₃alkyl-Y-C₁₋₃alkyl. In another preferred embodiment, L is C=O, Q is
25 absent, Y is selected from NH and N-C₁₋₆alkyl, and R⁵ and R⁶ together are C₁₋₃alkyl-Y-C₁₋₃alkyl. In another preferred embodiment, L is C=O, Y is absent, and R⁵ and R⁶
30

together are C₁₋₃alkyl-Y-C₁₋₃alkyl. In another preferred embodiment, L and A are C=O, and R⁵ and R⁶ together are C₁₋₂alkyl-ZA-C₁₋₂alkyl. In another preferred embodiment, L and A are C=O and R⁵ and R⁶ together are C₂₋₃alkyl-A.

5 In certain embodiments, R⁷ is selected from hydrogen and C₁₋₆alkyl. In certain preferred such embodiments, R⁷ is selected from hydrogen and methyl. In more preferred such embodiments, R⁷ is hydrogen.

10 In certain embodiments, R² and R³ are each independently C₁₋₆aralkyl, and R¹ is selected from C₁₋₆alkyl, C₁₋₆hydroxyalkyl, C₁₋₆alkoxyalkyl, aryl, and C₁₋₆aralkyl, any of which is optionally substituted with one or more of amide, amine, carboxylic acid (or a salt thereof), ester (including C₁₋₆alkyl ester, C₁₋₅alkyl ester, and aryl ester), thiol, or thioether substituents.

In certain preferred embodiments, the chain of amino acids has a structure of formula (XIV)



(XIV)

each Ar is independently an aromatic or heteroaromatic group optionally substituted with 1 to 4 substituents;

each A is independently selected from C=O, C=S, and SO₂, preferably C=O; or

20 A is optionally a covalent bond when adjacent to an occurrence of Z;

L is absent or is selected from C=O, C=S, and SO₂, preferably SO₂ or C=O;

M is absent or is C₁₋₁₂alkyl, preferably C₁₋₈alkyl;

Q is absent or is selected from O, NH, and N-C₁₋₆alkyl;

25 X is COOH or an activated form thereof, preferably X is COOH, COCl, or CON(Me)(OMe), most preferably X is COOH or COCl;

Y is absent or is selected from C=O and SO₂;

each Z is independently selected from O, S, NH, and N-C₁₋₆alkyl, preferably O; or

- Z is optionally a covalent bond when adjacent to an occurrence of A;
- R^2 is selected from aryl, C_{1-6} aralkyl, heteroaryl, and C_{1-6} heteroaralkyl;
- R^4 is $N(R^5)L-Q-R^6$;
- R^5 is selected from hydrogen, OH, C_{1-6} aralkyl, and C_{1-6} alkyl, preferably hydrogen;
- 5 R^6 is selected from hydrogen, C_{1-6} alkyl, C_{1-6} alkenyl, C_{1-6} alkynyl, Ar-Y-, carbocyclyl, heterocyclyl, an N-terminal protecting group, aryl, C_{1-6} aralkyl, heteroaryl, C_{1-6} heteroaralkyl, $R^{11}ZAZ-C_{1-8}$ alkyl-, $R^{14}Z-C_{1-8}$ alkyl-, $(R^{11}O)(R^{12}O)P(=O)O-C_{1-8}$ alkyl-ZAZ- C_{1-8} alkyl-, $R^{11}ZAZ-C_{1-8}$ alkyl-ZAZ- C_{1-8} alkyl-, heterocyclylM-ZAZ- C_{1-8} alkyl-, $(R^{11}O)(R^{12}O)P(=O)O-C_{1-8}$ alkyl-, $(R^{13})_2N-C_{1-12}$ alkyl-, $(R^{13})_3N^+-C_{1-12}$ alkyl-,
- 10 heterocyclylM-, carbocyclylM-, $R^{14}SO_2C_{1-8}$ alkyl-, and $R^{14}SO_2NH$; preferably an N-capping group, more preferably t-butoxycarbonyl or benzyloxycarbonyl; or
- R^5 and R^6 together are C_{1-6} alkyl-Y- C_{1-6} alkyl, C_{1-6} alkyl-ZAZ- C_{1-6} alkyl, ZAZ- C_{1-6} alkyl-ZAZ- C_{1-6} alkyl, ZAZ- C_{1-6} alkyl-ZAZ, or C_{1-6} alkyl-A, thereby forming a ring;
- R^9 is selected from hydrogen, OH, and C_{1-6} alkyl, preferably C_{1-6} alkyl; and
- 15 R^{10} is an N-terminal protecting group;
- R^{11} and R^{12} are independently selected from hydrogen, metal cation, C_{1-6} alkyl, C_{1-6} alkenyl, C_{1-6} alkynyl, aryl, heteroaryl, C_{1-6} aralkyl, and C_{1-6} heteroaralkyl, preferably from hydrogen, metal cation, and C_{1-6} alkyl, or R^{11} and R^{12} together are C_{1-6} alkyl, thereby forming a ring;
- 20 each R^{13} is independently selected from hydrogen and C_{1-6} alkyl, preferably C_{1-6} alkyl; and
- R^{14} is independently selected from hydrogen, C_{1-6} alkyl, C_{1-6} alkenyl, C_{1-6} alkynyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, C_{1-6} aralkyl, and C_{1-6} heteroaralkyl;
- 25 R^{15} is selected from hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} alkoxy, $-C(O)OC_{1-6}$ alkyl, $-C(O)NHC_{1-6}$ alkyl, and C_{1-6} aralkyl, preferably C_{1-6} alkyl and C_{1-6} hydroxyalkyl, more preferably methyl, ethyl, hydroxymethyl, and 2-hydroxyethyl;
- provided that in any occurrence of the sequence ZAZ, at least one member of the sequence must be other than a covalent bond.

In certain embodiments, R^5 is hydrogen, Q is absent, L is C=O or SO₂, and R^6 is selected from Ar-Y and heterocyclyl. In certain preferred such embodiments, heterocyclyl is selected from chromonyl, chromanyl, morpholino, and piperidinyl. In certain other preferred such embodiments, Ar is selected from phenyl, indolyl, benzofuranyl, naphthyl, quinoliny, quinolonyl, thienyl, pyridyl, pyrazyl, and the like.

In certain embodiments, R^5 is hydrogen, L is C=O or SO₂, Q is absent, and R^6 is C₁₋₆alkenyl, where C₁₋₆alkenyl is a substituted vinyl group where the substituent is preferably an aryl or heteroaryl group, more preferably a phenyl group optionally substituted with one to four substituents.

In certain embodiments, L and Q are absent and R^6 is selected from C₁₋₆alkyl, C₁₋₆alkenyl, C₁₋₆alkynyl, C₁₋₆aralkyl, and C₁₋₆heteroaralkyl. In certain such embodiments, R^5 is C₁₋₆alkyl and R^6 is selected from butyl, allyl, propargyl, phenylmethyl, 2-pyridyl, 3-pyridyl, and 4-pyridyl.

In other embodiments, L is SO₂, Q is absent, and R^6 is selected from C₁₋₆alkyl and aryl. In certain such embodiments, R^6 is selected from methyl and phenyl.

In certain embodiments, L is C=O and R^6 is selected from C₁₋₆alkyl, C₁₋₆alkenyl, C₁₋₆alkynyl, aryl, C₁₋₆aralkyl, heteroaryl, C₁₋₆heteroaralkyl, R^{11} ZA-C₁₋₈alkyl-, R^{14} Z-C₁₋₈alkyl-, $(R^{11}O)(R^{12}O)P(=O)O$ -C₁₋₈alkyl-, $(R^{11}O)(R^{12}O)P(=O)O$ -C₁₋₈alkyl-ZAZ-C₁₋₈alkyl-, $(R^{11}O)(R^{12}O)P(=O)O$ -C₁₋₈alkyl-Z-C₁₋₈alkyl-, R^{11} ZA-C₁₋₈alkyl-ZAZ-C₁₋₈alkyl-, heterocyclylMZA-C₁₋₈alkyl-, $(R^{13})_2N$ -C₁₋₈alkyl-, $(R^{13})_3N^+$ -C₁₋₈alkyl-, heterocyclylM-, carbocyclylM-, $R^{14}SO_2$ C₁₋₈alkyl-, and $R^{14}SO_2NH$ -, wherein each occurrence of Z and A is independently other than a covalent bond. In certain embodiments, L is C=O, Q is absent, and R^6 is H.

In certain embodiments, R^5 is C₁₋₆alkyl, R^6 is C₁₋₆alkyl, Q is absent, and L is C=O. In certain such embodiments, R^6 is ethyl, isopropyl, 2,2,2-trifluoroethyl, or 2-(methylsulfonyl)ethyl.

In other embodiments, L is C=O, Q is absent, and R^6 is C₁₋₆aralkyl. In certain such embodiments, R^6 is selected from 2-phenylethyl, phenylmethyl, (4-methoxyphenyl)methyl, (4-chlorophenyl)methyl, and (4-fluorophenyl)methyl.

In other embodiments, L is C=O, Q is absent, R⁵ is C₁₋₆alkyl, and R⁶ is aryl. In certain such embodiments, R⁶ is substituted or unsubstituted phenyl.

In certain embodiments, L is C=O, Q is absent, and R⁶ is selected from heteroaryl and C₁₋₆heteroaralkyl. In certain such embodiments, R⁶ is heteroaryl selected from
5 pyrrole, furan, thiophene, imidazole, isoxazole, oxazole, oxadiazole, thiazole, thiadiazole, triazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine. In certain alternative such embodiments, R⁶ is C₁₋₆heteroaralkyl selected from pyrrolylmethyl, furanylmethyl, thienylmethyl, imidazolylmethyl, isoxazolylmethyl, oxazolylmethyl, oxadiazolylmethyl, thiazolylmethyl, thiadiazolylmethyl, triazolylmethyl, pyrazolylmethyl, pyridylmethyl,
10 pyrazinylmethyl, pyridazinylmethyl and pyrimidinylmethyl.

In certain embodiments, L is C=O, Q is absent or O, and R⁶ is carbocyclylM-, wherein M is C₀₋₁alkyl. In certain such embodiments, R⁶ is cyclopropyl or cyclohexyl.

In certain embodiments, L and A are C=O, Q is absent, Z is O, M is C₁₋₈alkyl, preferably methylene, and R⁶ is selected from R¹¹ZA-C₁₋₈alkyl-, R¹⁴Z-C₁₋₈alkyl-, R¹¹ZA-C₁₋₈alkyl-ZAZ-C₁₋₈alkyl-, (R¹¹O)(R¹²O)P(=O)O-C₁₋₈alkyl-ZAZ-C₁₋₈alkyl-,
15 (R¹¹O)(R¹²O)P(=O)O-C₁₋₈alkyl-Z-C₁₋₈alkyl-, and heterocyclylMZA-C₁₋₈alkyl-, wherein each occurrence of A is independently other than a covalent bond. In certain such embodiments, R⁶ is heterocyclylMZA-C₁₋₈alkyl- where heterocyclyl is substituted or unsubstituted oxodioxolenyl or N(R¹⁶)(R¹⁷), wherein R¹⁶ and R¹⁷ together are C₁₋₆alkyl-Y-C₁₋₆alkyl, preferably C₁₋₃alkyl-Y-C₁₋₃alkyl, thereby forming a ring.
20

In certain preferred embodiments, L is C=O, Q is absent, M is C₁₋₈alkyl, and R⁶ is selected from (R¹¹O)(R¹²O)P(=O)O-C₁₋₈alkyl-, (R¹³)₂NC₁₋₈alkyl-, (R¹³)₃N⁺C₁₋₈alkyl-, and heterocyclyl-M-. In certain such embodiments, R⁶ is (R¹³)₂NC₁₋₈alkyl or (R¹³)₃N⁺C₁₋₈alkyl-, where R¹³ is C₁₋₆alkyl. In certain other such embodiments, R⁶ is heterocyclylM-,
25 where heterocyclyl is selected from morpholino, piperidino, piperazino, and pyrrolidino.


In certain embodiments, L is C=O, R⁵ is C₁₋₆alkyl, Q is selected from O and NH and R⁶ is selected from C₁₋₆alkyl, cycloalkyl-M, C₁₋₆aralkyl, and C₁₋₆heteroaralkyl. In other embodiments, L is C=O, R⁵ is C₁₋₆alkyl, Q is selected from O and NH, and R⁶ is C₁₋₆alkyl, where C₁₋₆alkyl is selected from methyl, ethyl, and isopropyl. In further
30 embodiments, L is C=O, R⁵ is C₁₋₆alkyl, Q is selected from O and NH and R⁶ is C₁₋₆aralkyl, where aralkyl is phenylmethyl. In other embodiments, L is C=O, R⁵ is C₁₋₆alkyl,

Q is selected from O and NH, and R⁶ is C₁₋₆heteroaralkyl, where heteroaralkyl is (4-pyridyl)methyl.

In certain embodiments, L is absent or is C=O, and R⁵ and R⁶ together are C₁₋₆alkyl-Y-C₁₋₆alkyl, C₁₋₆alkyl-ZA-C₁₋₆alkyl, or C₁₋₆alkyl-A, wherein each occurrence of Z and A is independently other than a covalent bond, thereby forming a ring. In certain preferred embodiments, L is C=O, Q and Y are absent, and R⁵ and R⁶ together are C₁₋₃alkyl-Y-C₁₋₃alkyl. In another preferred embodiment, L and Q are absent, and R⁵ and R⁶ together are C₁₋₃alkyl-Y-C₁₋₃alkyl. In another preferred embodiment, L is C=O, Q is absent, Y is selected from NH and N-C₁₋₆alkyl, and R⁵ and R⁶ together are C₁₋₃alkyl-Y-C₁₋₃alkyl. In another preferred embodiment, L is C=O, Y is absent, and R⁵ and R⁶ together are C₁₋₃alkyl-Y-C₁₋₃alkyl. In another preferred embodiment, L and A are C=O, and R⁵ and R⁶ together are C₁₋₂alkyl-ZA-C₁₋₂alkyl. In another preferred embodiment, L and A are C=O and R⁵ and R⁶ together are C₂₋₃alkyl-A.

In certain embodiments, R² is C₁₋₆aralkyl, and R¹ is selected from C₁₋₆alkyl, C₁₋₆hydroxyalkyl, C₁₋₆alkoxyalkyl, aryl, and C₁₋₆aralkyl, any of which is optionally substituted with one or more of amide, amine, carboxylic acid (or a salt thereof), ester (including C₁₋₆alkyl ester, C₁₋₅alkyl ester, and aryl ester), thiol, or thioether substituents.

In certain preferred embodiments, the chain of amino acids has a structure of formula (XV)



(XV)

wherein

L is selected from C=O, C=S, and SO₂, preferably C=O;

X is COOH or an activated form thereof, preferably X is COOH, COCl, or CON(Me)(OMe), most preferably X is COOH or COCl;

Z is absent, C₁₋₆alkyl, C₁₋₆alkoxy, or NR, e.g., absent, C₁₋₆alkyl, or C₁₋₆alkoxy, preferably absent;

R is selected from H and C₁₋₆alkyl, preferably H or CH₃;

R^1 and R^2 are each independently selected from hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} hydroxyalkyl, C_{1-6} alkoxyalkyl, aryl, C_{1-6} aralkyl, heteroaryl, heterocyclyl, C_{1-6} heterocycloalkyl, C_{1-6} heteroaralkyl, carbocyclyl, and C_{1-6} carbocyclolalkyl;

R^4 is selected from hydrogen, C_{1-6} aralkyl, and C_{1-6} alkyl;

5 R^5 is heteroaryl; and

R^6 is selected from hydrogen, C_{1-6} alkyl, and C_{1-6} aralkyl.

In certain embodiments, R^1 and R^2 are independently selected from hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} alkoxyalkyl, C_{1-6} aralkyl, C_{1-6} heterocycloalkyl, C_{1-6} heteroaralkyl, and C_{1-6} carbocyclolalkyl. In certain embodiments, R^1 and R^2 are
10 independently C_{1-6} alkyl selected from methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, and isobutyl. In certain embodiments, R^1 and R^2 are independently C_{1-6} hydroxyalkyl. In certain preferred such embodiments, R^1 and R^2 are independently selected from hydroxymethyl and hydroxyethyl, preferably hydroxymethyl. In certain embodiments, R^1 and R^2 are independently C_{1-6} alkoxyalkyl. In certain such embodiments, R^1 and R^2 are
15 independently selected from methoxymethyl and methoxyethyl, preferably methoxymethyl. In certain embodiments, R^1 and R^2 are independently C_{1-6} heteroaralkyl. In certain such embodiments, R^1 and R^2 are independently selected from imidazolylmethyl, pyrazolylmethyl, and thiazolylmethyl, and pyridylmethyl, preferably imidazol-4-ylmethyl, thiazol-4-ylmethyl, 2-pyridylmethyl, 3-pyridylmethyl, or 4-
20 pyridylmethyl. In certain embodiments, R^1 and R^2 are independently C_{1-6} aralkyl. In certain such embodiments, R^1 and R^2 are independently selected from phenylmethyl (benzyl) and phenylethyl, preferably phenylmethyl. In certain embodiments, R^1 and R^2 are independently C_{1-6} carbocycloalkyl. In certain such embodiments R^1 is cyclohexylmethyl. In certain embodiments R^1 and R^2 are different. In certain
25 embodiments, R^1 and R^2 are the same.

In certain embodiments, at least one of R^1 and R^2 is selected from C_{1-6} hydroxyalkyl and C_{1-6} alkoxyalkyl. In certain such embodiments, at least one of R^1 and R^2 is alkoxyalkyl. In certain such embodiments, at least one of R^1 and R^2 is selected from methoxymethyl and methoxyethyl.

30 In certain embodiments, R^4 and R^6 are independently selected from hydrogen and methyl, preferably hydrogen.

In certain embodiments, R⁵ is a 5- or 6-membered heteroaryl. In certain such embodiments, R⁵ is selected from isoxazole, isothiazole, furan, thiophene, oxazole, thiazole, pyrazole, or imidazole, preferably isoxazole, furan, or thiazole.

5 In certain embodiments, R⁵ is a bicyclic heteroaryl. In certain such embodiments bicyclic heteroaryl is selected from benzisoxazole, benzoxazole, benzothiazole, benzisothiazole.

In certain embodiments, L is C=O, Z is absent, and R⁵ is a 1,3-thiazol-5-yl or 1,3-thiazol-4-yl. In certain such embodiments, when the thiazole is substituted, it is substituted at least at the 2-position. In other such embodiments, R⁵ is an unsubstituted
10 1,3-thiazol-5-yl or 1,3-thiazol-4-yl.

In certain embodiments, L is C=O, Z is absent, and R⁵ is a substituted 1,3-thiazol-5-yl. In certain such embodiments, R⁵ is 1,3-thiazol-5-yl substituted with a substituent selected from C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkoxyalkyl, C₁₋₆hydroxyalkyl, carboxylic acid, aminocarboxylate, C₁₋₆alkylaminocarboxylate, (C₁₋₆alkyl)₂aminocarboxylate, C₁₋₆alkylcarboxylate, C₁₋₆heteroaralkyl, C₁₋₆aralkyl, C₁₋₆heterocycloalkyl, and C₁₋₆carbocycloalkyl. In certain preferred such embodiments, R⁵ is 1,3-thiazol-5-yl substituted with a substituent selected from methyl, ethyl, isopropyl, and cyclopropylmethyl.


20 In certain embodiments, L is C=O, Z is absent, and R⁵ is a substituted 1,3-thiazol-4-yl. In certain such embodiments, R⁵ is 1,3-thiazol-4-yl substituted with a substituent selected from C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkoxyalkyl, C₁₋₆hydroxyalkyl, carboxylic acid, aminocarboxylate, C₁₋₆alkylaminocarboxylate, (C₁₋₆alkyl)₂aminocarboxylate, C₁₋₆alkylcarboxylate, C₁₋₆heteroaralkyl, C₁₋₆aralkyl, C₁₋₆heterocycloalkyl, and C₁₋₆carbocycloalkyl. In certain preferred such embodiments, R⁵ is 1,3-thiazol-4-yl substituted with a substituent selected from methyl, ethyl, isopropyl, and cyclopropylmethyl.

In certain embodiments, L is C=O, Z is absent, and R⁵ is an isoxazol-3-yl or isoxazol-5-yl. In certain preferred such embodiments, when the isoxazol-3-yl is substituted, it is substituted at least at the 5-position. In certain preferred embodiments, when the isoxazol-5-yl is substituted, it is substituted at least at the 3-position.

In certain embodiments, L is C=O, Z is absent, and R⁵ is an unsubstituted isoxazol-3-yl.

5 In certain embodiments, L is C=O, Z is absent, and R⁵ is a substituted isoxazol-3-yl. In certain such embodiments, R⁵ is isoxazol-3-yl substituted with a substituent selected from C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkoxyalkyl, C₁₋₆hydroxyalkyl, carboxylic acid, aminocarboxylate, C₁₋₆alkylaminocarboxylate, (C₁₋₆alkyl)₂aminocarboxylate, C₁₋₆alkylcarboxylate, C₁₋₆heteroaralkyl, C₁₋₆aralkyl, C₁₋₆heterocycloalkyl, and C₁₋₆carbocycloalkyl. In certain preferred such embodiments R⁵ is isoxazole-3-yl substituted with a substituent selected from methyl, ethyl, isopropyl, and cyclopropylmethyl.

10 In certain embodiments L is C=O, Z is absent, and R⁵ is isoxazol-3-yl substituted with a 4- to 6-membered nitrogen-containing C₁₋₆heterocycloalkyl. In certain such embodiments, R⁵ is isoxazol-3-yl substituted with azetidinylmethyl, preferably azetidin-1-ylmethyl. In certain alternative such embodiments, L is C=O, Z is absent, and R⁵ is

15 isoxazol-3-yl substituted with , wherein W is O, NR, or CH₂, and R is H or C₁₋₆alkyl. In certain such embodiments, W is O.

In certain embodiments, L is C=O, Z is absent, and R⁵ is isoxazol-3-yl substituted with 5-membered nitrogen-containing C₁₋₆heteroaralkyl, such as pyrazolylmethyl, imidazolylmethyl, triazol-5-ylmethyl, preferably 1,2,4-triazol-5-ylmethyl.

20 In certain embodiments, L is C=O, Z is absent, and R⁵ is isoxazol-3-yl substituted with C₁₋₆alkoxy or C₁₋₆alkoxyalkyl, preferably methoxy, ethoxy, methoxymethyl, or methoxyethyl.


In certain embodiments, L is C=O, Z is absent, and R⁵ is isoxazol-3-yl substituted with C₁₋₆hydroxyalkyl, preferably hydroxymethyl or hydroxyethyl.

25 In certain embodiments, L is C=O, Z is absent, and R⁵ is isoxazol-3-yl substituted with a carboxylic acid, aminocarboxylate, C₁₋₆alkylaminocarboxylate, (C₁₋₆alkyl)₂aminocarboxylate, or C₁₋₆alkylcarboxylate. In certain such embodiments, R⁵ is substituted with methyl carboxylate or ethyl carboxylate, preferably methyl carboxylate.

In certain embodiments, L is C=O, Z is absent, and R⁵ is an unsubstituted isoxazol-5-yl.

In certain embodiments, L is C=O, Z is absent, and R⁵ is a substituted isoxazol-5-yl. In certain such embodiments, R⁵ is isoxazol-5-yl substituted with a substituent selected from C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkoxyalkyl, C₁₋₆hydroxyalkyl, carboxylic acid, aminocarboxylate, C₁₋₆alkylaminocarboxylate, (C₁₋₆alkyl)₂aminocarboxylate, C₁₋₆alkylcarboxylate, C₁₋₆heteroaralkyl, C₁₋₆aralkyl, C₁₋₆heterocycloalkyl, and C₁₋₆carbocycloalkyl. In certain preferred such embodiments R⁵ is isoxazole-5-yl substituted with a substituent selected from methyl, ethyl, isopropyl, and cyclopropylmethyl.

In certain embodiments L is C=O, Z is absent, and R⁵ is isoxazol-5-yl substituted with a 4- to 6-membered nitrogen-containing C₁₋₆heterocycloalkyl. In certain such embodiments, R⁵ is isoxazol-5-yl substituted with azetidinylmethyl, preferably azetidin-1-ylmethyl. In certain alternative such embodiments, L is C=O, Z is absent, and R⁵ is

isoxazol-5-yl substituted with , wherein W is O, NR, or CH₂, and R is H or C₁₋₆alkyl. In certain such embodiments, W is O.

In certain embodiments, L is C=O, Z is absent, and R⁵ is isoxazol-5-yl substituted with 5-membered nitrogen-containing C₁₋₆heteroaralkyl, such as pyrazolylmethyl, imidazolylmethyl, triazol-5-ylmethyl, preferably 1,2,4-triazol-5-ylmethyl.

In certain embodiments, L is C=O, Z is absent, and R⁵ is isoxazol-5-yl substituted with C₁₋₆alkoxy or C₁₋₆alkoxyalkyl, preferably methoxy, ethoxy, methoxymethyl, or methoxyethyl.

In certain embodiments, L is C=O, Z is absent, and R⁵ is isoxazol-5-yl substituted with C₁₋₆hydroxyalkyl, preferably hydroxymethyl or hydroxyethyl.

In certain embodiments, L is C=O, Z is absent, and R⁵ is isoxazol-5-yl substituted with a carboxylic acid, aminocarboxylate, C₁₋₆alkylaminocarboxylate, (C₁₋₆alkyl)₂aminocarboxylate, or C₁₋₆alkylcarboxylate. In certain such embodiments, R⁵ is substituted with methyl carboxylate or ethyl carboxylate, preferably methyl carboxylate.

In certain embodiments, Z is NR, preferably NH.

Uses of Enzyme Inhibitors

Orderly protein degradation is crucial to the maintenance of normal cell functions, and the proteasome is integral to the protein degradation process. The proteasome

controls the levels of proteins that are important for cell-cycle progression and apoptosis in normal and malignant cells; for example, cyclins, caspases, BCL2 and nF-kB (Kumatori et al., Proc. Natl. Acad. Sci. USA (1990) 87:7071-7075; Almond et al., Leukemia (2002) 16: 433-443). Thus, it is not surprising that inhibiting proteasome activity can translate into therapies to treat various disease states, such as malignant, non-malignant and autoimmune diseases, depending on the cells involved.

Both *in vitro* and *in vivo* models have shown that malignant cells, in general, are susceptible to proteasome inhibition. In fact, proteasome inhibition has already been validated as a therapeutic strategy for the treatment of multiple myeloma. This could be due, in part, to the highly proliferative malignant cell's dependency on the proteasome system to rapidly remove proteins (Rolfe et al., J. Mol. Med. (1997) 75:5-17; Adams, Nature (2004) 4: 349-360). Therefore, certain embodiments of the invention relate to a method of treating cancers comprising administering to a subject in need of such treatment an effective amount of the proteasome inhibitor compound disclosed herein.

As used herein, the term "cancer" includes, but is not limited to, blood born and solid tumors. Cancer refers to disease of blood, bone, organs, skin tissue and the vascular system, including, but not limited to, cancers of the bladder, blood, bone, brain, breast, cervix, chest, colon, endometrium, esophagus, eye, head, kidney, liver, lung, lymph nodes, mouth, neck, ovaries, pancreas, prostate, rectum, renal, skin, stomach, testis, throat, and uterus. Specific cancers include, but are not limited to, leukemia (acute lymphocytic leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), hairy cell leukemia), mature B cell neoplasms (small lymphocytic lymphoma, B cell prolymphocytic leukemia, lymphoplasmacytic lymphoma (such as Waldenström's macroglobulinemia), splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, monoclonal immunoglobulin deposition diseases, heavy chain diseases, extranodal marginal zone B cell lymphoma (MALT lymphoma), nodal marginal zone B cell lymphoma (NMZL), follicular lymphoma, mantle cell lymphoma, diffuse B cell lymphoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma and Burkitt lymphoma/leukemia), mature T cell and natural killer (NK) cell neoplasms (T cell prolymphocytic leukemia, T cell large granular lymphocytic leukemia, aggressive NK cell leukemia, adult T cell leukemia/lymphoma, extranodal NK/T cell

lymphoma, enteropathy-type T cell lymphoma, hepatosplenic T cell lymphoma, blastic
 NK cell lymphoma, mycosis fungoides (Sezary syndrome), primary cutaneous anaplastic
 large cell lymphoma, lymphomatoid papulosis, angioimmunoblastic T cell lymphoma,
 unspecified peripheral T cell lymphoma and anaplastic large cell lymphoma), Hodgkin
 5 lymphoma (nodular sclerosis, mixed cellularity, lymphocyte-rich, lymphocyte depleted or
 not depleted, nodular lymphocyte-predominant), myeloma (multiple myeloma, indolent
 myeloma, smoldering myeloma), chronic myeloproliferative disease,
 myelodysplastic/myeloproliferative disease, myelodysplastic syndromes,
 immunodeficiency-associated lymphoproliferative disorders, histiocytic and dendritic cell
 10 neoplasms, mastocytosis, chondrosarcoma, Ewing sarcoma, fibrosarcoma, malignant
 giant cell tumor, myeloma bone disease, osteosarcoma, breast cancer (hormone
 dependent, hormone independent), gynecological cancers (cervical, endometrial, fallopian
 tube, gestational trophoblastic disease, ovarian, peritoneal, uterine, vaginal and vulvar),
 basal cell carcinoma (BCC), squamous cell carcinoma (SCC), malignant melanoma,
 15 dermatofibrosarcoma protuberans, Merkel cell carcinoma, Kaposi's sarcoma,
 astrocytoma, pilocytic astrocytoma, dysembryoplastic neuroepithelial tumor,
 oligodendrogliomas, ependymoma, glioblastoma multiforme, mixed gliomas,
 oligoastrocytomas, medulloblastoma, retinoblastoma, neuroblastoma, germinoma,
 teratoma, malignant mesothelioma (peritoneal mesothelioma, pericardial mesothelioma,
 20 pleural mesothelioma), gastro-entero-pancreatic or gastroenteropancreatic neuroendocrine
 tumor (GEP-NET), carcinoid, pancreatic endocrine tumor (PET), colorectal
 adenocarcinoma, colorectal carcinoma, aggressive neuroendocrine tumor,
 leiomyosarcomamucinous adenocarcinoma, Signet Ring cell adenocarcinoma,
 hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, hemangioma, hepatic
 25 adenoma, focal nodular hyperplasia (nodular regenerative hyperplasia, hamartoma), non-
 small cell lung carcinoma (NSCLC) (squamous cell lung carcinoma, adenocarcinoma,
 large cell lung carcinoma), small cell lung carcinoma, thyroid carcinoma, prostate cancer
 (hormone refractory, androgen independent, androgen dependent, hormone-insensitive),
 and soft tissue sarcomas (fibrosarcoma, malignant fibrous hystiocyoma,
 30 dermatofibrosarcoma, liposarcoma, rhabdomyosarcoma leiomyosarcoma,
 hemangiosarcoma, synovial sarcoma, malignant peripheral nerve sheath
 tumor/neurofibrosarcoma, extraskletal osteosarcoma).

Many tumors of the haematopoietic and lymphoid tissues are characterized by an increase in cell proliferation, or a particular type of cell. The chronic myeloproliferative diseases (CMPDs) are clonal haematopoietic stem cell disorders characterized by proliferation in the bone marrow of one or more of the myeloid lineages, resulting in increased numbers of granulocytes, red blood cells and /or platelets in the peripheral blood. As such, the use of proteasome inhibitors for the treatment of such diseases is attractive and being examined (Cilloni et al., Haematologica (2007) 92: 1124-1229). CMPD can include chronic myelogenous leukaemia, chronic neutrophilic leukaemia, chronic eosinophilic leukaemia, polycythaemia vera, chronic idiopathic myelofibrosis, essential thrombocythaemia and unclassifiable chronic myeloproliferative disease. An aspect of the invention is the method of treating CMPD comprising administering to a subject in need of such treatment an effective amount of the proteasome inhibitor compound disclosed herein.

Myelodysplastic/myeloproliferative diseases, such as chronic myelomonocytic leukaemia, atypical chronic myeloid leukemia, juvenile myelomonocytic leukaemia and unclassifiable myelodysplastic/myeloproliferative disease, are characterized by hypercellularity of the bone marrow due to proliferation in one or more of the myeloid lineages. Inhibiting the proteasome with the composition described herein, can serve to treat these myelodysplastic/myeloproliferative diseases by providing a subject in need of such treatment an effective amount or the composition.

Myelodysplastic syndromes (MDS) refer to a group of hematopoietic stem cell disorders characterized by dysplasia and ineffective haematopoiesis in one or more of the major myeloid cell lines. Targeting NF-kB with a proteasome inhibitor in these hematologic malignancies induces apoptosis, thereby killing the malignant cell (Braun et al. Cell Death and Differentiation (2006) 13:748-758). A further embodiment of the invention is a method to treat MDS comprising administering to a subject in need of such treatment an effective amount of the compound disclosed herein. MDS includes refractory anemia, refractory anemia with ringed sideroblasts, refractory cytopenia with multilineage dysplasia, refractory anemia with excess blasts, unclassifiable myelodysplastic syndrome and myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality.

Mastocytosis is a proliferation of mast cells and their subsequent accumulation in one or more organ systems. Mastocytosis includes, but is not limited to, cutaneous mastocytosis, indolent systemic mastocytosis (ISM), systemic mastocytosis with associated clonal haematological non-mast-cell-lineage disease (SM-AHNMD), aggressive systemic mastocytosis (ASM), mast cell leukemia (MCL), mast cell sarcoma (MCS) and extracutaneous mastocytoma. Another embodiment of the invention is a method to treat mastocytosis comprising administering an effective amount of the compound disclosed herein to a subject diagnosed with mastocytosis.

The proteasome regulates NF- κ B, which in turn regulates genes involved in the immune and inflammatory response. For example, NF- κ B is required for the expression of the immunoglobulin light chain κ gene, the IL-2 receptor α -chain gene, the class I major histocompatibility complex gene, and a number of cytokine genes encoding, for example, IL-2, IL-6, granulocyte colony-stimulating factor, and IFN- β (Palombella et al., *Cell* (1994) 78:773-785). Thus, in certain embodiments, the invention relates to methods of affecting the level of expression of IL-2, MHC-I, IL-6, TNF α , IFN- β or any of the other previously-mentioned proteins, each method comprising administering to a subject an effective amount of a proteasome inhibitor composition disclosed herein. In certain embodiments, the invention includes a method of treating an autoimmune disease in a mammal comprising administering a therapeutically effective amount of the compound described herein. An "autoimmune disease" herein is a disease or disorder arising from and directed against an individual's own tissues. Examples of autoimmune diseases or disorders include, but are not limited to, inflammatory responses such as inflammatory skin diseases including psoriasis and dermatitis (e.g. atopic dermatitis); systemic sclerosis and scleroderma; responses associated with inflammatory bowel disease (such as Crohn's disease and ulcerative colitis); respiratory distress syndrome (including adult respiratory distress syndrome; ARDS); dermatitis; meningitis; encephalitis; uveitis; colitis; glomerulonephritis; allergic conditions such as eczema and asthma and other conditions involving infiltration of T cells and chronic inflammatory responses; atherosclerosis; leukocyte adhesion deficiency; rheumatoid arthritis; systemic lupus erythematosus (SLE); diabetes mellitus (e.g. Type I diabetes mellitus or insulin dependent diabetes mellitus); multiple sclerosis; Reynaud's syndrome; autoimmune thyroiditis; allergic encephalomyelitis; Sjorgen's syndrome; juvenile onset diabetes; and immune

responses associated with acute and delayed hypersensitivity mediated by cytokines and T-lymphocytes typically found in tuberculosis, sarcoidosis, polymyositis, granulomatosis and vasculitis; pernicious anemia (Addison's disease); diseases involving leukocyte diapedesis; central nervous system (CNS) inflammatory disorder; multiple organ injury syndrome; hemolytic anemia (including, but not limited to cryoglobulinemia or Coombs positive anemia); myasthenia gravis; antigen-antibody complex mediated diseases; anti-glomerular basement membrane disease; antiphospholipid syndrome; allergic neuritis; Graves' disease; Lambert-Eaton myasthenic syndrome; pemphigoid bullous; pemphigus; autoinimmune polyendocrinopathies; Reiter's disease; stiff-man syndrome; Beheet disease; giant cell arteritis; immune complex nephritis; IgA nephropathy; IgM polyneuropathies; immune thrombocytopenic purpura (ITP) or autoimmune thrombocytopenia.

The immune system screens for autologous cells that are virally infected, have undergone oncogenic transformation or present unfamiliar peptides on their surface. Intracellular proteolysis generate small peptides for presentation to T-lymphocytes to induce MHC class I-mediated immune responses. Thus, in certain embodiments, the invention relates to a method of using the compound as an immunomodulatory agent for inhibiting or altering antigen presentation in a cell, comprising exposing the cell (or administering to a subject) to the compound described herein. Specific embodiments include a method of treating graft or transplant-related diseases, such as graft-versus-host disease or host versus-graft disease in a mammal, comprising administering a therapeutically effective amount of the compound described herein. The term "graft" as used herein refers to biological material derived from a donor for transplantation into a recipient. Grafts include such diverse material as, for example, isolated cells such as islet cells; tissue such as the amniotic membrane of a newborn, bone marrow, hematopoietic precursor cells, and ocular tissue, such as corneal tissue; and organs such as skin, heart, liver, spleen, pancreas, thyroid lobe, lung, kidney, tubular organs (e.g., intestine, blood vessels, or esophagus). The tubular organs can be used to replace damaged portions of esophagus, blood vessels, or bile duct. The skin grafts can be used not only for burns, but also as a dressing to damaged intestine or to close certain defects such as diaphragmatic hernia. The graft is derived from any mammalian source, including human, whether from cadavers or living donors. In some cases, the donor and recipient is the same mammal.

Preferably the graft is bone marrow or an organ such as heart and the donor of the graft and the host are matched for HLA class II antigens.

Histiocytic and dendritic cell neoplasms are derived from phagocytes and accessory cells, which have major roles in the processing and presentation of antigens to lymphocytes. Depleting the proteasome content in dendritic cells has been shown to alter their antigen-induced responses (Chapatte et al. Cancer Res. (2006) 66:5461-5468). Thus, another embodiment of the invention comprises administering an effective amount of the composition disclosed herein to a subject with histiocytic or dendritic cell neoplasm. Histiocytic and dendritic cell neoplasms include histiocytic sarcoma, Langerhans cell histiocytosis, Langerhans cell sarcoma, interdigitating dendritic cell sarcoma/tumor, follicular dendritic cell sarcoma/tumor and non-specified dendritic cell sarcoma.

Inhibition of the proteasome has been shown to be beneficial to treat diseases whereby a cell type is proliferating and immune disorders; thus, an embodiment of the invention includes the treatment of lymphoproliferative diseases (LPD) associated with primary immune disorders (PID) comprising administering an effective amount of the disclosed compound to a subject in need thereof. The most common clinical settings of immunodeficiency associated with an increased incidence of lymphoproliferative disorders, including B-cell and T-cell neoplasms and lymphomas, are primary immunodeficiency syndromes and other primary immune disorders, infection with the human immunodeficiency virus (HIV), iatrogenic immunosuppression in patients who have received solid organ or bone marrow allografts, and iatrogenic immunosuppression associated with methotrexate treatment. Other PIDs commonly associated with LPDs, but not limited to, are ataxia telangiectasia (AT), Wiskott-Aldrich syndrome (WAS), common variable immunodeficiency (CVID), severe combined immunodeficiency (SCID), X-linked lymphoproliferative disorder (XLP), Nijmegen breakage syndrome (NBS), hyper-IgM syndrome, and autoimmune lymphoproliferative syndrome (ALPS).

Additional embodiments of the invention relate to methods for affecting the proteasome-dependent regulation of oncoproteins and methods of treating or inhibiting cancer growth, each method comprising exposing a cell (*in vivo*, e.g., in a subject, or *in vitro*) to the proteasome inhibitor composition disclosed herein. HPV-16 and HPV-18-derived E6 proteins stimulate ATP- and ubiquitin-dependent conjugation and degradation

of p53 in crude reticulocyte lysates. The recessive oncogene p53 has been shown to accumulate at the nonpermissive temperature in a cell line with a mutated thermolabile E1. Elevated levels of p53 may lead to apoptosis. Examples of proto-oncoproteins degraded by the ubiquitin system include c-Mos, c-Fos, and c-Jun. In certain
5 embodiments, the invention relates to a method for treating p53-related apoptosis, comprising administering to a subject an effective amount of a proteasome inhibitor composition disclosed herein.

Another aspect of the invention relates to the use of proteasome inhibitor compositions disclosed herein for the treatment of neurodegenerative diseases and
10 conditions, including, but not limited to, stroke, ischemic damage to the nervous system, neural trauma (e.g., percussive brain damage, spinal cord injury, and traumatic damage to the nervous system), multiple sclerosis and other immune-mediated neuropathies (e.g., Guillain-Barre syndrome and its variants, acute motor axonal neuropathy, acute inflammatory demyelinating polyneuropathy, and Fisher Syndrome), HIV/AIDS
15 dementia complex, axonomy, diabetic neuropathy, Parkinson's disease, Huntington's disease, multiple sclerosis, bacterial, parasitic, fungal, and viral meningitis, encephalitis, vascular dementia, multi-infarct dementia, Lewy body dementia, frontal lobe dementia such as Pick's disease, subcortical dementias (such as Huntington or progressive supranuclear palsy), focal cortical atrophy syndromes (such as primary aphasia),
20 metabolic-toxic dementias (such as chronic hypothyroidism or B12 deficiency), and dementias caused by infections (such as syphilis or chronic meningitis).

Alzheimer's disease is characterized by extracellular deposits of β -amyloid protein (β -AP) in senile plaques and cerebral vessels. β -AP is a peptide fragment of 39 to 42 amino acids derived from an amyloid protein precursor (APP). At least three isoforms of
25 APP are known (695, 751, and 770 amino acids). Alternative splicing of mRNA generates the isoforms; normal processing affects a portion of the β -AP sequence, thereby preventing the generation of β -AP. It is believed that abnormal protein processing by the proteasome contributes to the abundance of β -AP in the Alzheimer brain. The APP-processing enzyme in rats contains about ten different subunits (22 kDa-32 kDa). The 25
30 kDa subunit has an N-terminal sequence of X-Gln-Asn-Pro-Met-X-Thr-Gly-Thr-Ser, which is identical to the β -subunit of human macropain (Kojima, S. et al., *Fed. Eur.*

Biochem. Soc., (1992) 304:57-60). The APP-processing enzyme cleaves at the Gln¹⁵--Lys¹⁶ bond; in the presence of calcium ion, the enzyme also cleaves at the Met⁻¹--Asp¹ bond, and the Asp¹--Ala² bonds to release the extracellular domain of β -AP.

One aspect of the invention, therefore, relates to a method of treating Alzheimer's disease, comprising administering to a subject an effective amount of the proteasome inhibitor composition disclosed herein. Such treatment includes reducing the rate of β -AP processing, reducing the rate of β -AP plaque formation, reducing the rate of β -AP generation, and reducing the clinical signs of Alzheimer's disease.

Fibrosis is the excessive and persistent formation of fibrous connective tissue resulting from the hyperproliferative growth of fibroblasts and is associated with activation of the TGF- β signaling pathway. Fibrosis involves extensive deposition of extracellular matrix and can occur within virtually any tissue or across several different tissues. Normally, the level of intracellular signaling protein (Smad) that activate transcription of target genes upon TGF- β stimulation is regulated by proteasome activity (Xu et al., 2000). However, accelerated degradation of the TGF- β signaling components has been observed in fibrotic conditions, such as cystic fibrosis, injection fibrosis, endomyocardial fibrosis, idiopathic pulmonary fibrosis, myelofibrosis, retroperitoneal fibrosis, progressive massive fibrosis, nephrogenic systemic fibrosis. Other conditions that are often associated with fibrosis include cirrhosis, diffuse parenchymal lung disease, post-vasectomy pain syndrome, tuberculosis, sickle-cell anemia and rheumatoid arthritis. An embodiment of the invention is the method of treating a fibrotic or fibrotic-associated condition comprising administering an effective amount of the composition described herein to a subject in need of such treatment.

The treatment of burn victims is often hampered by fibrosis, thus, in certain embodiments, the invention relates to the topical or systemic administration of the inhibitors to treat burns. Wound closure following surgery is often associated with disfiguring scars, which may be prevented by inhibition of fibrosis. Thus, in certain embodiments, the invention relates to a method for the prevention or reduction of scarring.

Overproduction of lipopolysaccharide (LPS)-induced cytokines such as TNF α is considered to be central to the processes associated with septic shock. Furthermore, it is

generally accepted that the first step in the activation of cells by LPS is the binding of LPS to specific membrane receptors. The α - and β -subunits of the 20S proteasome complex have been identified as LPS-binding proteins, suggesting that the LPS-induced signal transduction may be an important therapeutic target in the treatment or prevention of sepsis (Qureshi, N. et al., *J. Immun.* (2003) 171: 1515-1525). Therefore, in certain embodiments, the proteasome inhibitor composition may be used for the inhibition of TNF α to prevent and/or treat septic shock.

Ischemia and reperfusion injury results in hypoxia, a condition in which there is a deficiency of oxygen reaching the tissues of the body. This condition causes increased degradation of I κ B- β , thereby resulting in the activation of NF- κ B (Koong et al., 1994). It has been demonstrated that the severity of injury resulting in hypoxia can be reduced with the administration of a proteasome inhibitor (Gao et al., 2000; Bao et al., 2001; Pye et al., 2003). Therefore, certain embodiments of the invention relate to a method of treating an ischemic condition or reperfusion injury comprising administering to a subject in need of such treatment an effective amount of the proteasome inhibitor compound disclosed herein. Examples of such conditions or injuries include, but are not limited to, acute coronary syndrome (vulnerable plaques), arterial occlusive disease (cardiac, cerebral, peripheral arterial and vascular occlusions), atherosclerosis (coronary sclerosis, coronary artery disease), infarctions, heart failure, pancreatitis, myocardial hypertrophy, stenosis, and restenosis.

NF- κ B also binds specifically to the HIV-enhancer/promoter. When compared to the Nef of mac239, the HIV regulatory protein Nef of pbj14 differs by two amino acids in the region which controls protein kinase binding. It is believed that the protein kinase signals the phosphorylation of I κ B, triggering I κ B degradation through the ubiquitin-proteasome pathway. After degradation, NF- κ B is released into the nucleus, thus enhancing the transcription of HIV (Cohen, J., *Science*, (1995) 267:960). In certain embodiments, the invention relates to a method for inhibiting or reducing HIV infection in a subject, or a method for decreasing the level of viral gene expression, each method comprising administering to the subject an effective amount of the proteasome inhibitor composition disclosed herein.

Viral infections contribute to the pathology of many diseases. Heart conditions such as ongoing myocarditis and dilated cardiomyopathy have been linked to the

coxsackievirus B3. In a comparative whole-genome microarray analyses of infected mouse hearts, specific proteasome subunits were uniformly up-regulated in hearts of mice which developed chronic myocarditis (Szalay et al, Am J Pathol 168:1542-52, 2006).

Some viruses utilize the ubiquitin-proteasome system in the viral entry step where the

5 virus is released from the endosome into the cytosol. The mouse hepatitis virus (MHV)

belongs to the *Coronaviridae* family, which also includes the severe acute respiratory

syndrome (SARS) coronavirus. Yu and Lai (J Virol 79:644-648, 2005) demonstrated that

treatment of cells infected with MHV with a proteasome inhibitor resulted in a decrease

in viral replication, correlating with reduced viral titer as compared to that of untreated

10 cells. The human hepatitis B virus (HBV), a member of the *Hepadnaviridae* virus family,

likewise requires virally encoded envelop proteins to propagate. Inhibiting the

proteasome degradation pathway causes a significant reduction in the amount of secreted

envelope proteins (Simsek et al, J Virol 79:12914-12920, 2005). In addition to HBV,

other hepatitis viruses (A, C, D and E) may also utilize the ubiquitin-proteasome

15 degradation pathway for secretion, morphogenesis and pathogenesis. Accordingly, in

certain embodiments, the invention relates to a method for treating viral infection, such as

SARS or hepatitis A, B, C, D and E, comprising contacting a cell with (or administering

to a subject) an effective amount of the compound disclosed herein.

In certain embodiments, the disclosed compositions may be useful for the

20 treatment of a parasitic infection, such as infections caused by protozoan parasites. The

proteasome of these parasites is considered to be involved primarily in cell differentiation and replication activities (Paugam et al., Trends Parasitol. 2003, 19(2): 55-59).

Furthermore, entamoeba species have been shown to lose encystation capacity when

exposed to proteasome inhibitors (Gonzales, et al., Arch. Med. Res. 1997, 28, Spec No:

25 139-140). In certain such embodiments, the administrative protocols for the proteasome

inhibitor compositions are useful for the treatment of parasitic infections in humans

caused by a protozoan parasite selected from Plasmodium sps. (including P. falciparum,

P. vivax, P. malariae, and P. ovale, which cause malaria), Trypanosoma sps. (including T.

cruzi, which causes Chagas' disease, and T. brucei which causes African sleeping

30 sickness), Leishmania sps. (including L. amazonensis, L. donovani, L. infantum, L.

mexicana, etc.), Pneumocystis carinii (a protozoan known to cause pneumonia in AIDS

and other immunosuppressed patients), Toxoplasma gondii, Entamoeba histolytica,

Entamoeba invadens, and Giardia lamblia. In certain embodiments, the disclosed proteasome inhibitor compositions are useful for the treatment of parasitic infections in animals and livestock caused by a protozoan parasite selected from Plasmodium hermani, Cryptosporidium sps., Echinococcus granulosus, Eimeria tenella, Sarcocystis neurona, and Neurospora crassa. Other compounds that act as proteasome inhibitors in the treatment of parasitic diseases are described in WO 98/10779, which is incorporated herein in its entirety.

In certain embodiments, the proteasome inhibitor compositions inhibit proteasome activity in a parasite without recovery in red blood cells and white blood cells. In certain such embodiments, the long half-life of blood cells may provide prolonged protection with regard to therapy against recurring exposures to parasites. In certain embodiments, the proteasome inhibitor compositions may provide prolonged protection with regard to chemoprophylaxis against future infection.

Prokaryotes have what is equivalent to the eukaryote 20S proteasome particle. Albeit, the subunit composition of the prokaryote 20S particle is simpler than that of eukaryotes, it has the ability to hydrolyze peptide bonds in a similar manner. For example, the nucleophilic attack on the peptide bond occurs through the threonine residue on the N-terminus of the β -subunits. Thus, an embodiment of this invention relates to a method of treating prokaryotic infections, comprising administering to a subject an effective amount of the proteasome inhibitor composition disclosed herein. Prokaryotic infections may include diseases caused by either mycobacteria (such as tuberculosis, leprosy or Buruli Ulcer) or archaebacteria.

It has also been demonstrated that inhibitors that bind to the 20S proteasome stimulate bone formation in bone organ cultures. Furthermore, when such inhibitors have been administered systemically to mice, certain proteasome inhibitors increased bone volume and bone formation rates over 70% (Garrett, I. R. et al., *J. Clin. Invest.* (2003) 111: 1771-1782), therefore suggesting that the ubiquitin-proteasome machinery regulates osteoblast differentiation and bone formation. Therefore, the disclosed proteasome inhibitor composition may be useful in the treatment and/or prevention of diseases associated with bone loss, such as osteoporosis.

Thus, in certain embodiments, the invention relates to a method for treating a disease or condition selected from cancer, autoimmune disease, graft or transplant-related condition, neurodegenerative disease, fibrotic-associated condition, ischemic-related conditions, infection (viral, parasitic or prokaryotic) and diseases associated with bone loss, comprising administering a crystalline compound of Formula (II).

Compounds prepared as described herein can be administered in various forms, depending on the disorder to be treated and the age, condition, and body weight of the patient, as is well known in the art. For example, where the compounds are to be administered orally, they may be formulated as tablets, capsules, granules, powders, or syrups; or for parenteral administration, they may be formulated as injections (intravenous, intramuscular, or subcutaneous), drop infusion preparations, or suppositories. For application by the ophthalmic mucous membrane route, they may be formulated as eye drops or eye ointments. These formulations can be prepared by conventional means, and if desired, the active ingredient may be mixed with any conventional additive or excipient, such as a binder, a disintegrating agent, a lubricant, a corrigent, a solubilizing agent, a suspension aid, an emulsifying agent, a coating agent, a cyclodextrin, and/or a buffer. Although the dosage will vary depending on the symptoms, age and body weight of the patient, the nature and severity of the disorder to be treated or prevented, the route of administration and the form of the drug, in general, a daily dosage of from 0.01 to 2000 mg of the compound is recommended for an adult human patient, and this may be administered in a single dose or in divided doses. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect.

The precise time of administration and/or amount of the composition that will yield the most effective results in terms of efficacy of treatment in a given patient will depend upon the activity, pharmacokinetics, and bioavailability of a particular compound, physiological condition of the patient (including age, sex, disease type and stage, general physical condition, responsiveness to a given dosage, and type of medication), route of administration, etc. However, the above guidelines can be used as the basis for fine-tuning the treatment, e.g., determining the optimum time and/or amount of administration, which will require no more than routine experimentation consisting of monitoring the subject and adjusting the dosage and/or timing.

5 The phrase “pharmaceutically acceptable” is employed herein to refer to those ligands, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

10 The phrase “pharmaceutically acceptable carrier” as used herein means a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose, and sucrose; (2) starches, such as corn starch, potato starch, and substituted or unsubstituted β -cyclodextrin; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) 15 talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol, and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer’s solution; (19) ethyl 20 alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations. In certain embodiments, pharmaceutical compositions of the present invention are non-pyrogenic, i.e., do not induce significant temperature elevations when administered to a patient.

25 The term “pharmaceutically acceptable salt” refers to the relatively non-toxic, inorganic and organic acid addition salts of the inhibitor(s). These salts can be prepared in situ during the final isolation and purification of the inhibitor(s), or by separately reacting a purified inhibitor(s) in its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed. Representative salts include the hydrobromide, 30 hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, laurylsulphonate

salts, and amino acid salts, and the like. (See, for example, Berge et al. (1977)
“Pharmaceutical Salts”, J. Pharm. Sci. 66: 1-19.)

In other cases, the inhibitors useful in the methods of the present invention may contain one or more acidic functional groups and, thus, are capable of forming
5 pharmaceutically acceptable salts with pharmaceutically acceptable bases. The term
“pharmaceutically acceptable salts” in these instances refers to the relatively non-toxic inorganic and organic base addition salts of an inhibitor(s). These salts can likewise be prepared in situ during the final isolation and purification of the inhibitor(s), or by
10 separately reacting the purified inhibitor(s) in its free acid form with a suitable base, such as the hydroxide, carbonate, or bicarbonate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary, or tertiary amine. Representative alkali or alkaline earth salts include the lithium, sodium, potassium, calcium, magnesium, and aluminum salts, and the like. Representative organic amines useful for the formation of base addition salts include ethylamine,
15 diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, and the like (see, for example, Berge et al., *supra*).

Wetting agents, emulsifiers, and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring, and perfuming agents, preservatives and antioxidants can also be
20 present in the compositions.

Examples of pharmaceutically acceptable antioxidants include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite, and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin,
25 propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.

Formulations suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-
30 aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or

syrup, or as pastilles (using an inert matrix, such as gelatin and glycerin, or sucrose and acacia) and/or as mouthwashes, and the like, each containing a predetermined amount of an inhibitor(s) as an active ingredient. A composition may also be administered as a bolus, electuary, or paste.

5 In solid dosage forms for oral administration (capsules, tablets, pills, dragees, powders, granules, and the like), the active ingredient is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, cyclodextrins, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example,
10 carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, acetyl
15 alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and (10) coloring agents. In the case of capsules, tablets, and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and
20 hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols, and the like.

 A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative,
25 disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered inhibitor(s) moistened with an inert liquid diluent.

 Tablets, and other solid dosage forms, such as dragees, capsules, pills, and
30 granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient

therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes, and/or microspheres. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents, and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols, and fatty acid esters of sorbitan, and mixtures thereof.

Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming, and preservative agents.

Suspensions, in addition to the active inhibitor(s) may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.

Formulations for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more inhibitor(s) with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, which is solid at room

temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active agent.

Formulations which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams, or spray formulations containing such carriers as
5 are known in the art to be appropriate.

Dosage forms for the topical or transdermal administration of an inhibitor(s) include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, and inhalants. The active component may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants
10 which may be required.

The ointments, pastes, creams, and gels may contain, in addition to inhibitor(s), excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc, and zinc oxide, or mixtures thereof.

Powders and sprays can contain, in addition to an inhibitor(s), excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates, and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
15

The inhibitor(s) can be alternatively administered by aerosol. This is accomplished by preparing an aqueous aerosol, liposomal preparation, or solid particles containing the composition. A nonaqueous (e.g., fluorocarbon propellant) suspension could be used. Sonic nebulizers are preferred because they minimize exposing the agent to shear, which can result in degradation of the compound.
20

Ordinarily, an aqueous aerosol is made by formulating an aqueous solution or suspension of the agent together with conventional pharmaceutically acceptable carriers and stabilizers. The carriers and stabilizers vary with the requirements of the particular composition, but typically include nonionic surfactants (Tweens, Pluronics, sorbitan esters, lecithin, Cremophors), pharmaceutically acceptable co-solvents such as
25 polyethylene glycol, innocuous proteins like serum albumin, oleic acid, amino acids such
30

as glycine, buffers, salts, sugars, or sugar alcohols. Aerosols generally are prepared from isotonic solutions.

Transdermal patches have the added advantage of providing controlled delivery of an inhibitor(s) to the body. Such dosage forms can be made by dissolving or dispersing the agent in the proper medium. Absorption enhancers can also be used to increase the flux of the inhibitor(s) across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the inhibitor(s) in a polymer matrix or gel.

Pharmaceutical compositions of this invention suitable for parenteral administration comprise one or more inhibitors(s) in combination with one or more pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.

Examples of suitable aqueous and nonaqueous carriers which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include tonicity-adjusting agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.

In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. For example, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.

5 Injectable depot forms are made by forming microcapsule matrices of inhibitor(s) in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared
10 by entrapping the drug in liposomes or microemulsions which are compatible with body tissue.

The preparations of agents may be given orally, parenterally, topically, or rectally. They are, of course, given by forms suitable for each administration route. For example, they are administered in tablets or capsule form, by injection, inhalation, eye lotion,
15 ointment, suppository, infusion; topically by lotion or ointment; and rectally by suppositories. Oral administration is preferred.

The phrases “parenteral administration” and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular,
20 intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection, and infusion.

The phrases “systemic administration,” “administered systemically,” “peripheral administration” and “administered peripherally” as used herein mean the administration
25 of a ligand, drug, or other material other than directly into the central nervous system, such that it enters the patient’s system and thus, is subject to metabolism and other like processes, for example, subcutaneous administration.

These inhibitors(s) may be administered to humans and other animals for therapy by any suitable route of administration, including orally, nasally, as by, for example, a
30 spray, rectally, intravaginally, parenterally, intracisternally, and topically, as by powders, ointments or drops, including buccally and sublingually.

Regardless of the route of administration selected, the inhibitor(s), which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art.

5 Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.

10 The concentration of a disclosed compound in a pharmaceutically acceptable mixture will vary depending on several factors, including the dosage of the compound to be administered, the pharmacokinetic characteristics of the compound(s) employed, and the route of administration. In general, the compositions of this invention may be provided in an aqueous solution containing about 0.1-10% w/v of a compound disclosed herein, among other substances, for parenteral administration. Typical dose ranges are
15 from about 0.01 to about 50 mg/kg of body weight per day, given in 1-4 divided doses. Each divided dose may contain the same or different compounds of the invention. The dosage will be an effective amount depending on several factors including the overall health of a patient, and the formulation and route of administration of the selected compound(s).


20 The term “C_{x-y}alkyl” refers to substituted or unsubstituted saturated hydrocarbon groups, including straight-chain alkyl and branched-chain alkyl groups that contain from x to y carbons in the chain, including haloalkyl groups such as trifluoromethyl and 2,2,2-trifluoroethyl, etc. C₀alkyl indicates a hydrogen where the group is in a terminal position, a bond if internal. The terms “C_{2-y}alkenyl” and “C_{2-y}alkynyl” refer to substituted or
25 unsubstituted unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond respectively.

 The term “alkoxy” refers to an alkyl group having an oxygen attached thereto. Representative alkoxy groups include methoxy, ethoxy, propoxy, tert-butoxy and the like. An “ether” is two hydrocarbons covalently linked by an oxygen. Accordingly, the
30 substituent of an alkyl that renders that alkyl an ether is or resembles an alkoxy.

The term “C₁₋₆alkoxyalkyl” refers to a C₁₋₆alkyl group substituted with an alkoxy group, thereby forming an ether.


The term “C₁₋₆aralkyl”, as used herein, refers to a C₁₋₆alkyl group substituted with an aryl group.

- 5 The terms “amine” and “amino” are art-recognized and refer to both unsubstituted and substituted amines and salts thereof, e.g., a moiety that can be represented by the general formulae:



- 10 wherein R⁹, R¹⁰ and R^{10'} each independently represent a hydrogen, an alkyl, an alkenyl, -(CH₂)_m-R⁸, or R⁹ and R¹⁰ taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure; R⁸ represents an aryl, a cycloalkyl, a cycloalkenyl, a heterocyclyl or a polycyclyl; and m is zero or an integer from 1 to 8. In preferred embodiments, only one of R⁹ or R¹⁰ can be a carbonyl, e.g., R⁹, R¹⁰, and the nitrogen together do not form an imide. In even more preferred
- 15 embodiments, R⁹ and R¹⁰ (and optionally R^{10'}) each independently represent a hydrogen, an alkyl, an alkenyl, or -(CH₂)_m-R⁸. In certain embodiments, the amino group is basic, meaning the protonated form has a pK_a ≥ 7.00.

The terms “amide” and “amido” are art-recognized as an amino-substituted carbonyl and includes a moiety that can be represented by the general formula:




- 20 wherein R⁹, R¹⁰ are as defined above. Preferred embodiments of the amide will not include imides which may be unstable.

- The term “aryl” as used herein includes 5-, 6-, and 7-membered substituted or unsubstituted single-ring aromatic groups in which each atom of the ring is carbon. The
- 25 term “aryl” also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the

rings is aromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryl, and/or heterocyclyls. Aryl groups include benzene, naphthalene, phenanthrene, phenol, aniline, and the like.

5 The terms “carbocycle” and “carbocyclyl”, as used herein, refer to a non-aromatic substituted or unsubstituted ring in which each atom of the ring is carbon. The terms “carbocycle” and “carbocyclyl” also include polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is carbocyclic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryl, and/or heterocyclyls.

10 The term “carbonyl” is art-recognized and includes such moieties as can be represented by the general formula:



15 wherein X is a bond or represents an oxygen or a sulfur, and R^{11} represents a hydrogen, an alkyl, an alkenyl, $-(\text{CH}_2)_m-\text{R}^8$ or a pharmaceutically acceptable salt, $\text{R}^{11'}$ represents a hydrogen, an alkyl, an alkenyl or $-(\text{CH}_2)_m-\text{R}^8$, where m and R^8 are as defined above. Where X is an oxygen and R^{11} or $\text{R}^{11'}$ is not hydrogen, the formula represents an “ester”. Where X is an oxygen, and R^{11} is a hydrogen, the formula represents a “carboxylic acid”.

20 The terms “heteroaryl” includes substituted or unsubstituted aromatic 5- to 7-membered ring structures, more preferably 5- to 6-membered rings, whose ring structures include one to four heteroatoms. The term “heteroaryl” also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is heteroaromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryl, and/or heterocyclyls. Heteroaryl groups include, for example, pyrrole, furan, thiophene, 25 imidazole, oxazole, thiazole, triazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine, and the like.

The term “heteroatom” as used herein means an atom of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, phosphorus, and sulfur.

The terms “heterocyclyl” or “heterocyclic group” refer to substituted or unsubstituted non-aromatic 3- to 10-membered ring structures, more preferably 3- to 7-membered rings, whose ring structures include one to four heteroatoms. The term terms “heterocyclyl” or “heterocyclic group” also include polycyclic ring systems having two or
5 more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is heterocyclic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryl, and/or heterocyclyls. Heterocyclyl groups include, for example, piperidine, piperazine, pyrrolidine, morpholine, lactones, lactams, and the like.

10 The term “C₁₋₆hydroxyalkyl” refers to a C₁₋₆alkyl group substituted with a hydroxy group.

The terms “polycyclyl” or “polycyclic” refer to two or more rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryl, and/or heterocyclyls) in which two or more carbons are common to two adjoining rings, e.g., the rings are “fused
15 rings”. Each of the rings of the polycycle can be substituted or unsubstituted.

The term “proteasome” as used herein is meant to include immuno- and constitutive proteasomes.

The term “substantially pure” as used herein, refers to a crystalline polymorph that is greater than 90% pure, meaning that contains less than 10% of any other compound,
20 including the corresponding amorphous compound. Preferably, the crystalline polymorph is greater than 95% pure, or even greater than 98% pure.

The term “substituted” refers to moieties having substituents replacing a hydrogen on one or more carbons of the backbone. It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance
25 with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. As used herein, the term “substituted” is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic,
30 branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds. The permissible substituents can be one or more and

the same or different for appropriate organic compounds. For purposes of this invention, the heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms. Substituents can include, for example, a halogen, a hydroxyl, a carbonyl (such as a carboxyl, an alkoxycarbonyl, a formyl, or an acyl), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an alkoxyl, a phosphoryl, a phosphate, a phosphonate, a phosphinate, an amino, an amido, an amidine, an imine, a cyano, a nitro, an azido, a sulfhydryl, an alkylthio, a sulfate, a sulfonate, a sulfamoyl, a sulfonamido, a sulfonyl, a heterocyclyl, an aralkyl, or an aromatic or heteroaromatic moiety. It will be understood by those skilled in the art that the moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate.

A “therapeutically effective amount” of a compound with respect to the subject method of treatment, refers to an amount of the compound(s) in a preparation which, when administered as part of a desired dosage regimen (to a mammal, preferably a human) alleviates a symptom, ameliorates a condition, or slows the onset of disease conditions according to clinically acceptable standards for the disorder or condition to be treated or the cosmetic purpose, e.g., at a reasonable benefit/risk ratio applicable to any medical treatment.


The term “thioether” refers to an alkyl group, as defined above, having a sulfur moiety attached thereto. In preferred embodiments, the “thioether” is represented by -S-alkyl. Representative thioether groups include methylthio, ethylthio, and the like.

As used herein, the term “treating” or “treatment” includes reversing, reducing, or arresting the symptoms, clinical signs, and underlying pathology of a condition in manner to improve or stabilize a subject's condition.

Exemplification

Example 1

Synthesis of Compound 1



5

Synthesis of (B)

Hydroxybenztriazole (HOBT) (10.81 g, 80.0 mmol) and DIEA (200.0 mmol, 25.85 g, 35 mL) was added to a solution of NBoc leucine (50.0 mmol, 11.56 g) and phenylalanine methyl ester (50.0 mmol, 10.78 g) in 500 mL of DMF. The mixture was cooled to 0 °C in an ice-water bath and benzotriazol-1-yloxytris(dimethylamino)-phosphonium hexafluorophosphate (BOP) (80.0 mmol, 35.38 g) was added in several portions over five minutes. The reaction was placed under an atmosphere of argon and

10

stirred overnight. The reaction was diluted with brine (1000 mL) and extracted with EtOAc (5 x 200 mL). The organic layers were combined and washed with water (10 x 100 mL) and brine (2 x 150 mL) and dried over MgSO₄. The MgSO₄ was removed by filtration and the volatiles removed under reduced pressure to give (A) (18.17 g). To a 50 mL 0 °C cooled solution of 80% TFA/DCM was added BocNHLeuPheOMe (45.86 mmol, 18.0 g). The solution was stirred and allowed to warm to room temperature over 2 hr. The volatiles were removed under reduced pressure to give an oil. BocNHhPhe (45.86 mmol, 12.81 g), DMF (500 mL), HOBT (73.37 mmol, 9.91 g) and DIEA (183.44 mmol, 23.70 g, 32.0 mL) were then added to the oil. The mixture was cooled to 0 °C in an ice-water bath and BOP (73.37 mmol, 32.45 g) was added in several portions over five minutes. The reaction was placed under argon and allowed to warm to room temperature overnight. The reaction was diluted with H₂O (1500 mL) and extracted with DCM (5 x 300 mL). The organic layers were combined and washed with H₂O (6 x 300 mL) and brine (1 x 300 mL) and dried over MgSO₄. The MgSO₄ was removed by filtration and the volatiles removed under reduced pressure to give a yellow solid. EtOH (200 mL, 95%) was then added to the yellow solid and the mixture was heated to 65 °C to dissolve all of the solids. The solution was then added to 1000 mL of chilled H₂O and the resulting precipitate collected to give (B) (21.59 g).

Synthesis of (C)

(B) (1.80 mmol, 1.0 g) was mixed with TFA/DCM (80%) and was stirred at room temperature for 1 hr, at which time the mixture was concentrated and placed under high vacuum for 2 hr giving the TFA salt of the tri-peptide amine. To a 0 °C solution of the TFA salt (1.80 mmol) in DMF (10 mL) was added DIEA (3.6 mmol, 0.7 mL) followed by chloroacetyl chloride (2.7 mmol, 0.215 mL). The reaction was allowed to warm to RT while stirring overnight under an atmosphere of nitrogen. The mixture was then diluted with brine (15 mL) and extracted with EtOAc (3 x 15 mL). The organic layers were combined, washed with H₂O (2x15 mL) and brine (2 x 15 mL) and dried over Na₂SO₄. The Na₂SO₄ was removed by filtration and the volatiles removed under reduced pressure. The crude material was suspended in EtOAc and filtered to give (C) (0.640 g)

Synthesis of (D)

KI (0.019 mmol, 0.0032 g) and morpholine (0.110 mmol, 0.0096 g) were added to a solution of (C) (0.094 mmol, 0.050 g) in THF (10 mL) and the mixture was stirred overnight under an atmosphere of nitrogen. The volatiles were removed under reduced pressure and the crude material taken up in EtOAc (15 mL), washed with H₂O (2x10 mL) and brine (2x10 mL) and dried over MgSO₄. The MgSO₄ was removed by filtration and the volatiles removed under reduced pressure to give (D).

Synthesis of (E)

LiOH (0.94 mmol, 0.023 g) was added to a slurry of (D) (0.094 mmol) in 4 mL of 3:1 MeOH/H₂O cooled to 0 °C. After 12 hr at 5 °C the reaction was quenched with 20 mL sat. NH₄Cl and diluted further with 10 mL H₂O. The pH of the reaction mixture was adjusted to 3 with 1 N HCl, extracted with DCM (3 x 15 mL), and dried over MgSO₄. The MgSO₄ was removed by filtration and the volatiles were removed under reduced pressure to give (E).

Synthesis of Compound 1

(E) (0.082 mmol, 0.046 g), DIEA (0.328 mmol, 0.057 mL) and HOBT (0.133 mmol, 0.018 g) were added to a stirred solution of (F) (0.082 mmol) in DMF (2 mL). The mixture was cooled to 0 °C in an ice bath and BOP (0.131 mmol, 0.058 g) was added in several portions. The mixture was stirred at 5 °C under an atmosphere of argon overnight. The reaction was then diluted with H₂O (15 mL) and extracted with EtOAc. The organic layer was washed with water, sat. NaHCO₃, and brine and dried over anhydrous MgSO₄. The MgSO₄ was removed by filtration and the volatiles removed under reduced pressure to give compound **1** (0.034 g) (IC₅₀ 20S CT-L<100nM; IC₅₀ Cell-Based CT-L<100nM).

Example 2

Compound **1** (1.0 g) was dissolved in methanol (16 mL) heated to 80 °C. Water (4 mL) was then slowly added and the clear solution was allowed to cool to ambient temperature and the solution was brought to supersaturation by evaporating off 10 mL of solvent with compressed air. The resulting crystals were filtered, washed with 8 mL 1:1

deionized water-methanol, and dried under vacuum for 12 hours to provide crystalline compound **1** (0.9 g) with a melting point of 212 °C.

The characteristic DSC curve of the sample is shown in Figure 1 as recorded on a TA Instruments Differential Scanning Calorimeter 2920 at a heating rate of 10 °C/minute.

5 *Example 3*

Compound **1** (1.0 g) was dissolved in acetonitrile (17 mL) heated to 80 °C. Water (8 mL) was then slowly added and the clear solution was allowed to cool to ambient temperature and the solution was brought to supersaturation by evaporating off 10 mL of solvent with compressed air. The resulting crystals were filtered, washed with 8 mL 1:1
10 deionized water-acetonitrile, and dried under vacuum for 12 hours to provide crystalline compound **1** (0.85 g) with a melting point of 212 °C.

Example 4

Compound **1** (1.0 g) was dissolved in ethanol (17 mL) heated to 80 °C. Water (5 mL) was then slowly added and the clear solution was allowed to cool to ambient
15 temperature and the solution was brought to supersaturation by evaporating off 15 mL of solvent with compressed air. The resulting crystals were filtered, washed with 8 mL 1:1 deionized water-ethanol, and dried under vacuum for 12 hours to provide crystalline compound **1** (0.82 g) with a melting point of 212 °C.

Example 5


20 Compound **1** (1.0 g) was dissolved in ethyl acetate (30 mL) heated to 80 °C. Water (5 mL) was then slowly added and the clear solution was allowed to cool to ambient temperature and the solution was brought to supersaturation by evaporating off 20 mL of solvent with compressed air. The resulting crystals were filtered, washed with 5 mL ethyl acetate, and dried under vacuum for 12 hours to provide crystalline compound
25 **1** (0.60 g) with a melting point of 212 °C.

Example 6

Compound **1** (1.0 g) was dissolved in ethanol (15 mL) heated to 80 °C. Water (5 mL) was then slowly added and the clear solution was allowed to cool to ambient temperature and the solution was brought to supersaturation by evaporating off 10 mL of
30 solvent with compressed air. The resulting crystals were filtered, washed with 10 mL 1:1

deionized water-ethanol, and dried under vacuum for 12 hours to provide crystalline compound **1** (0.54 g) with a melting point of 212 °C.

Example 7



5 Synthesis of (F)

Compound (G) (0.43 g) was prepared according to U.S. Pat. Application No. 2005-0256324 and was added to a flask along with Pd/C (10% wt, 0.10 g) followed by slow addition of TFA (35 mL). The flask was evacuated and back-flushed with hydrogen gas three times and then the reaction mixture was stirred under one atmosphere of hydrogen at room temperature for two hours. The reaction mixture was then filtered through Celite and the filtrate was concentrated under reduced pressure. Dichloromethane (25 mL) was added and the volatiles removed under reduced pressure. The resultant thick yellow syrup was dried under high vacuum to a constant weight. The syrup was then transferred to 50 mL volumetric flask and rinsed with 8.5 mL diethyl ether to yield crystalline compound (F) (0.33g).

Synthesis of Compound **1**

A 10 mL volumetric flask was charged with 1-hydroxybenzotriazole (HOBT, 0.54 g) and N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 1.54 g) and diluted to 50 mL with DMF. This stock solution of coupling reagents was 0.40 M for both HOBT and HBTU.

(E) (0.61 g), (F) (0.33g), and the coupling reagent stock solution (2.7 mL), were added to a 10 mL volumetric flask and the mixture was cooled to 0 °C. DIEA (0.56 mL) was then added dropwise to the cooled solution. The mixture was allowed to stir at 0 °C for 60 minutes and was then quenched by the addition of saturated sodium bicarbonate (15 mL). The mixture was diluted with ethyl acetate (35 mL) and the layers separated. The organic layer was washed saturated sodium bicarbonate (3 x 15 mL), brine (2 x 15 mL) and dried over sodium sulfate. The sodium sulfate was removed by filtration and the volatiles removed under reduced pressure to give a thick syrup which was further dried under high vacuum to give a crude compound **1** as a foam (0.59 g).

10 *Example 8*

Crude compound **1** (0.590 g) was completely dissolved in methanol (11 mL) by stirring and heating in an oil bath (80 °C) and deionized water (17 mL) was added dropwise. The mixture was seeded with crystalline compound **1**, stirred and allowed to slowly evaporate for 12 hours to approximately 20 mL to precipitate compound **1**. The suspension was filtered, washed with 1:1 deionized water-methanol (4 mL), and dried under vacuum for 12 hours at room temperature to yield compound **1** as a white solid (0.25 g). The crystallization was repeated two additional times to yield crystalline compound **1** (0.13 g).

Crystalline compound **1** (0.3 g) was dissolved in isopropanol (15 mL) by stirring and heating in an oil bath (80 °C). The solution was concentrated under reduced pressure to reduce volume to 5 mL. Deionized water (20 mL) was quickly added and the resultant suspension was rigorously stirred for 1 hour. The glassy precipitate was filtered, rinsed with deionized water (25 mL) and dried to yield amorphous Compound **1** (0.3 g).

The characteristic DSC curve of the amorphous sample is shown in Figure 7 which was recorded on a TA Instruments Differential Scanning Calorimeter 2920 at a heating rate of 1 °C/minute for the amorphous form of Compound **1**.

The characteristic X-ray diffraction pattern of the amorphous powder is shown in Figure 8 and was recorded on the Shimadzu XRD-6000 under Cu K α radiation [voltage and current set at 40 kV and 40 mA; divergence and scattering slits set at 1° and receiving slit set at 0.15 mm; NaI scintillation detector used for diffracted radiation; a θ -2 θ continuous scan at 3°/min (0.4 sec/0.02° step) from 2.5 to 40° 2 θ was used; samples were

placed in an aluminum holder with silicon insert; and data collected and analyzed with XRD-6100/7000 v.5.0].

Example 9

Synthesis of (F)

5 A flask was charged with (G) and ethyl acetate (400 mL) and the solution was cooled in an ice bath for 15 minutes with stirring. Trifluoroacetic acid (200 mL) was added dropwise, maintaining an internal temperature of less than 10 °C. Pd/C (3.6 g) was added in one portion and the flask was purged under high vacuum and refilled with hydrogen three times. After 2 hours, the reaction was filtered through Celite and the
10 filtrate evaporated under reduced pressure to a thick orange oil which was swirled gently with 170 mL diethyl ether. As the flask was swirled, fine crystals formed. The flask was allowed to sit at room temperature, and rapid crystallization occurred. After 1 hour at ambient temperature, the flask was capped tightly and placed in the freezer overnight (< -5 °C). The resulting crystalline solid was filtered and washed with ice cold ethyl ether
15 (50 mL) and dried under high vacuum. Fine white crystals (14.1 g; melting point: 137 °C) of (F) were obtained.


Synthesis of Compound 1

 A flask was charged with (F) (10 g), (E) (15.3 g), HBTU (15.3 g), HOBt (5.5 g), and DMF (300mL). The mixture was stirred vigorously until dissolved and was placed in
20 an NaCl/ice bath (-5 °C). After 15 minutes, DIEA (7.1 mL) was added dropwise over <10 minutes, maintaining an internal temperature of less than -3 °C. After addition was complete, the reaction mixture was stirred in the bath for one hour and was quenched by addition of saturated NaHCO₃ (aq.) (200 mL). The slurry was extracted with ethyl acetate (1.5 L) and the organic layer was washed with sat. NaHCO₃(aq.) (2 x 300 mL)
25 and sat. NaCl (aq.) (200 mL), and then dried over MgSO₄.

 The organic layer was concentrated to ~50 mL under reduced pressure and methylethyl ketone (200 mL) was added, and the solution was again concentrated to ~50 mL. Methylethyl ketone (125 mL) was added again, and the solution was stirred in an oil bath (80 °C) until clear. The solution was then allowed to cool and was seeded with pure
30 crystalline Compound 1. The mixture was stirred for 2 hours at 25 °C and then overnight at 0 °C. The white solid precipitate was filtered and washed with ice cold methylethyl

ketone (300 mL) to give white solids. The solid was dried under high vacuum at ambient temperature to a constant weight to yield 13.5 g of pure compound **1**.

Example 10



5 *Synthesis of (F)*

A flask was charged with (H) (100 g) [see: Bioorg. Med. Chem. Letter 1999, 9, 2283-88], and dichloromethane (300 mL) under nitrogen and the solution was cooled in an ice bath to 0-5 °C. Trifluoroacetic acid (136.9 mL) was added dropwise with stirring at 0-10 °C, after which the reaction mixture was removed from the ice bath and stirred at room temperature for 2 hours. Methyl tert-butyl ether (300 mL) was then added and 400 mL of solvent was evaporated under reduced pressure. MTBE (200 mL) was then added via addition funnel and the solution stirred for 20 minutes at 20 °C, then heptanes (1000 mL) were added within 10 minutes and the reaction mixture cooled to 0-5 °C. The reaction mixture was stirred for 30 minutes and then the solids were filtered, rinsed with cold heptanes (0-5 °C, 3 x 100 mL) and dried under high vacuum to the constant weight to yield 90.69 g of (F) as a white solid.

Synthesis of Compound 1

A solution of (F) (137.53 g) in DMF (900 mL) was cooled in a NaCl/ice bath to -2 °C. HBTU (138.06 g), HOBT (55.90 g), (F) (90.00 g) and ice cold DMF (180 mL) were then added to the solution followed by addition of neat DIEA (67.19 g, 509.66 mmol) via a dropping funnel at a rate such that the internal temperature remained at ~0 °C. After

two hours, neat isopropylethylamine (24.0 g) was added via a dropping funnel. The mixture was stirred at 0 °C until conversion >99%. The reaction mixture was then transferred portionwise into a dropping funnel and slowly added to an ice cold half-saturated NaHCO₃ solution (3.6 L) (internal temperature maintained at 20 °C). The
5 resulting slurry was stirred with a mechanical stirrer for 30 minutes and the solids were then filtered and the filter cake washed with ice cold water (2 x 1350 mL). The solids were then dissolved in dichloromethane (2.7 L) and the organic phase was extracted with water (portions of 2700 mL) until relative percent area for HOBt/HBTU was <15% by HPLC (200 µL solution for HPLC sample). The organic phase was filtered through a
10 plug of sodium sulfate and subsequently inline filtered through a pad of active charcoal.

The organic phase was concentrated under reduced pressure and methylethyl ketone (1350 mL) was added and the solution concentrated again under reduced pressure. Methylethyl ketone (1350 mL) was then added and the solution concentrated again under reduced pressure. The resulting concentrated solution was cooled to 0 °C until solids
15 were formed; then the mixture was heated to 75 °C as more methylethyl ketone was added (ca. 750 mL) until complete dissolution. The solution was cooled to 65 °C and seeded and the resulting solution/slurry was cooled at a rate of 0.5 °C/minute to 20 °C (stir rate of 60-70 rpm). The slurry was stirred for a minimum of 5 hours at 20 °C to allow for complete crystallization. The solids were filtered off and washed with ice cold
20 methylethyl ketone (720 mL) and the filter cake was dried under a stream of nitrogen for 1 hour. The solids were transferred into a round bottom flask and dried under reduced pressure to constant weight to yield 116 g of crystalline compound **1**.

Example 11

Methanol (200 mL) was added to crude Compound **1** and the mixture was
25 concentrated to 100 mL. Additional methanol (275 mL) was added, along with deionized water (75 mL), and the mixture concentrated to 400 mL. The clear solution was then seeded with pure crystalline Compound **1**, stirred and allowed to slowly evaporate under a stream of compressed air to 200 mL. The resulting yellowish solid was washed with deionized water (400 mL) and 1:1 deionized water-methanol (300 mL) until it turned
30 white and filtrate turned clear. Compound **1** was then dried under vacuum for 12 hours.

The resulting compound **1** (17.3 g) was completely dissolved in methanol (275 mL) by stirring and heating in oil bath (bath set at 85 °C; mixture temperature less than 65 °C). Deionized water (75 mL) was added dropwise over 15 minutes, and the clear mixture was allowed to cool to room temperature. Seed crystals of compound **1** were added to the stirred solution, and the mixture was allowed to slowly concentrate under a stream of compressed air to approximately 250 mL over 9 hours. The crystals were then filtered and washed with 1:1 deionized water-methanol (300 mL). The white solid was dried under vacuum for 12 hours at 22 °C to yield crystalline compound **1** (14.0 g).

Example 12

Crude compound **1** (12.1 g) was completely dissolved in methanol (50 mL) by stirring and heating in oil bath (bath set at 85 °C; mixture temperature less than 65 °C). The clear solution was allowed to cool to room temperature and seed crystals of compound **1** were added to the solution. The mixture was allowed to crystallize over three hours at room temperature. The resulting solid was washed with 1:1 deionized water-methanol (500 mL), filtered, and dried under vacuum for 12 hours to yield crystalline compound **1** (9.4 g).

Example 13

Synthesis of (F)

A flask was charged with (H) (1 g) and ethyl acetate (20 mL) and the solution was cooled in an ice bath for 15 minutes with stirring. Trifluoroacetic acid (10 mL) was then added dropwise, while maintaining an internal temperature of less than 3 °C. After stirring at 0 °C for 2 hours, the reaction was allowed to warm to ambient temperature and was stirred for two additional hours. The solution was then evaporated under reduced pressure to a thick colorless oil. This crude mixture was swirled gently with 10 mL of diethyl ether and as the solution was swirled, fine crystals formed. After 30 minutes at ambient temperature, the flask was capped tightly and placed in the freezer overnight. The resulting crystalline solid was filtered and washed with ice cold diethyl ether, and then dried on high vacuum to a constant weight to give fine white crystals of (F) (670 mg).

Example 14

Synthesis of Compound 1

Compound (E) (14.2 g), HBTU (14.3 g), HOBT (5.1 g) and DMF (300 mL), were added to (F) and the mixture was stirred at room temperature to complete dissolution.

5 The reaction was cooled in ice bath for 15 minutes, and DIEA (32 mL) was added over 15 minutes while maintaining an internal temperature of less than 10 °C. The reaction mixture was then stirred at 0 °C for one hour before it was quenched with saturated sodium bicarbonate (200 mL). The mixture was extracted with ethyl acetate (1.5 L), and the organic layer was washed with saturated sodium bicarbonate (2 x300 mL) and
10 deionized water (1 x 200 mL). The combined aqueous wash was extracted with ethyl acetate (200 mL) and the organic layers were combined (1.7 L).

The combined organic layers (1.7 L) were concentrated under reduced pressure to 100 mL followed by addition of methanol (200 mL), and the mixture was again concentrated to 100 mL. Additional methanol (200 mL) was added, deionized water (75
15 mL) was slowly added with stirring, and the mixture concentrated to 300 mL. The clear solution was seeded with crystalline compound 1, stirred and allowed to slowly concentrate under a stream of compressed air to about 200 mL. The off-white solid was washed until solid turned white and filtrate turned clear with a 4:1 deionized water-methanol (2 L) and 1:1 deionized water-methanol (500 mL). The resulting solid was
20 dried under vacuum for 12 hours at 22 °C to provide compound 1 (16.8 g).

Compound 1 was completely dissolved in ethanol (200 mL) by stirring and heating in oil bath (bath set at 85 °C; mixture temperature less than 65 °C). The clear solution was allowed to cool to room temperature and seed crystals of compound 1 were added to the stirred solution, and the mixture was flushed with air and allowed to
25 crystallize. The mixture was then filtered, washed with 1:1 deionized water-ethanol (200 mL), and dried under vacuum for 12 hours at room temperature to yield 10.2 g of crystalline compound 1.

Example 15

Synthesis of (F)

A 500 mL flask was equipped with a mechanical stirrer, thermocouple, cooling bath. (G) (12.5 g) was dissolved in ethyl acetate (125 mL) and the clear solution was
5 cooled to 0-5 °C followed by slow addition of trifluoroacetic acid (375 mL) such that the internal temperature was maintained below 10 °C. After warming to room temperature, 5% Pd/C (1.25 g) was added and the reaction mixture under an atmosphere of hydrogen for 2 hours. The reaction mixture was filtered through a glass fiber and rinsed with ethyl acetate (50 mL). The filtrate was then concentrated under reduced pressure to yield a
10 yellow oil. MTBE (50 mL) was added to the oil and co-evaporated to yellow oil at 25 °C. MTBE (60 mL) was again added and the mixture was cooled to -10 °C and stirred for 60 minutes. Heptanes (120 mL) were then slowly added to the stirred mixture and stirring was continued at -10 °C for an additional 15 minutes. The solids were collected by filtration and the crystals were rinsed with heptanes (2 x 40 mL) and dried under high
15 vacuum at room temperature (22 °C) to a constant weight (10.1 g).

Synthesis of Compound 1

A flask equipped with a mechanical stirrer, thermocouple, cooling bath, nitrogen inlet and drying tube was charged with DMF, (F) (133.9 g), (E) (241.8 g), HBTU (242.8 g), and HOBT (86.5 g) and the mixture was stirred and cooled to 0-5 °C. DIEA (156 mL)
20 was then added slowly over at least 30 minutes, while maintaining temperature between 0-5 °C. The reaction mixture was stirred at 0-5 °C for one hour and was then poured into a vigorously stirred saturated solution of sodium bicarbonate (3630 mL) and ethyl acetate (900 mL). Additional ethyl acetate (2000 mL) was added to extract the product and the organic layer was separated. The aqueous layer was then extracted with ethyl acetate
25 (1930 mL). The organic phases were combined and washed with saturated solution of sodium bicarbonate (2420 mL) and brine (2420 mL), dried over magnesium sulfate (360 g), filtered through glass fiber filter and rinsed with ethyl acetate (2 x 360 mL).

The resulting solution was concentrated to a semisolid under reduced pressure and methanol (725 mL) was added and co-evaporated under reduced pressure to yield semi-
30 solid compound 1. The crude product was dissolved in methanol (5320 mL) and the solution was stirred while water (2130 mL) was added over twenty minutes. When

addition of water was complete, approximately 0.3 g of pure crystalline seeds were added and the methanol/water solution was stirred for three hours. The resulting crystalline white solid was isolated by filtration and the fine white crystalline product was rinsed with a methanol/water solution (1:1, 1200 mL). The resulting solid was rinsed with
5 methanol/water solution (1:1, 1200 mL) and the crystalline product was poured onto drying tray and dried to a constant weight under high vacuum at 27 °C under nitrogen bleed to yield crystalline compound **1** (230 g).

Example 16

Synthesis of (F)

10 A 100 mL three-neck round bottom flask was charged with (G) (5 g) and dichloromethane (15 mL). The mixture was stirred until the solids had dissolved, and then placed in an ice bath. After 20 minutes, the internal temperature had reached 0.6 °C and trifluoroacetic acid was added dropwise over 5 min. After the addition was complete, the flask was allowed to warm to room temperature. After 2 hours, MTBE was added to
15 the flask (35 mL) and the mixture was cooled in an ice bath, wherein (F) began to crystallize during cooling. Heptanes (65 mL) were then added to the flask dropwise over 15 min and the flask was placed in the freezer (-5 °C). After 1 hour, the solid white product was collected and washed with heptanes (10 mL) to provide 4.57 g of (F).


Example 17

20 *Synthesis of Compound 1 Citrate Salt*

Compound **1** (10 g) and citric acid (2.7 g) were dissolved in THF (75 mL) and acetonitrile (50 mL). The solution was then stirred for 2 hours at room temperature, at which time a white precipitate formed. The flask was then cooled to -10 °C and stirred overnight. The solids were filtered and washed with 100 mL acetonitrile to give 11.52 g
25 of the citrate salt of compound **1**.

Example 18

Synthesis of (H) and (Q)



5 Synthesis of (I)

A suspension of dimethyl hydroxylamine hydrochloride (10.53 g, 108 mmol) in DCM (270 mL) under an atmosphere of argon was stirred vigorously for 0.5 hours followed by addition of TEA (10.92 g, 14.75 mL, 108 mmol) via addition funnel. A solution of Boc-Leucine-OH (25.0 g, 108 mmol) in DCM (270 mL) was cooled to 0 °C followed by dropwise addition of isobutylchloroformate (14.73 g, 13.98 mL, 108 mmol) via addition funnel. The mixture was further cooled to -20 °C and NMM (10.92 g, 11.87 mL, 108 mmol) was added via addition funnel at such a rate to maintain the internal temperature below -10 °C. After stirring for 5 minutes at -20 °C, the previously prepared dimethylhydroxylamine solution was added via a wide bore Teflon cannula. The reaction mixture was removed from the cooling bath and allowed to warm to room temperature overnight. The mixture was then diluted with water (100 mL) and stirred for 15 minutes.

The layers were separated and the aqueous layer extracted with DCM (2 x 50 mL). The organic layers were combined, washed with 1 N HCl (4 x 150 mL), water (1 x 150 mL), sat. NaHCO₃ (2 x 100 mL), brine (1 x 250 mL) and dried over Na₂SO₄. The Na₂SO₄ was removed by filtration and the volatiles removed under reduced pressure to give (I) (28.05 g, 102 mmol).

Synthesis of (J)

To a 0 °C solution of (I) (10.0 g, 36.4 mmol,) in 100 mL of dry THF, under an atmosphere of argon was added isopropenyl magnesium bromide (364 mL, 182 mmol, 5.0 eq, 0.5 M solution in THF) dropwise using an addition funnel. The rate of addition was adjusted such that the internal reaction temperature was maintained below 5 °C. After six hours the reaction mixture was poured into 250 mL of sat. NH₄Cl and 500 mL wet ice. After stirring for 30 minutes the mixture became clear and the volatiles were removed under reduced pressure and the crude material diluted with EtOAc (200 mL). The layers were separated and the aqueous layer extracted with EtOAc (3 x 150 mL), the organic layers were combined, washed with water (2 x 150 mL), brine (2 x 150 mL) and dried over MgSO₄. The MgSO₄ was removed by filtration and the volatiles removed under reduced pressure. Purification by flash chromatography (15:1 hexanes/ EtOAc) gave (J) as a solid (7.5 g, 29.37 mmol).

Synthesis of (K) and (L)

To a 0 °C solution of (J) (5.0 g, 19.58 mmol) in 200 mL of MeOH was added CeCl₃·7H₂O (8.75 g, 23.50 mmol). The solution was stirred under an atmosphere of argon until the CeCl₃·7H₂O was completely dissolved. To this solution was added NaBH₄ (0.88 g, 23.50 mmol) in 10 portions over 2 minutes. The reaction was then stirred under an atmosphere of argon at 0 °C for 6 hours. The reaction was quenched at 0 °C with approximately 2.5 mL of glacial HOAc and after 30 minutes of additional stirring at 0 °C the mixture become clear. The volatiles were removed under reduced pressure and the remaining oil taken up in EtOAc (200 mL). The organic layer was washed with water (2 x 100 mL), brine (2 x 100 mL) and dried over MgSO₄. The MgSO₄ was removed by filtration and the volatiles removed under reduced pressure giving (K) and (L) as a waxy, white solid (4.75 g, 18.5 mmol). Ratio of diastereomers 4.5:1 as determined by HPLC.

Synthesis of (M), (N), (O) and (P)


To a solution of (K) and (L) (0.025 g, 0.097 mmol) in DCM (1 mL) was added *m*CPBA (0.018 g, 0.107 mmol). The mixture was stirred at room temperature for one hour at which time the mixture was diluted with sat. NaHCO₃ (5 mL). The layers were separated and the aqueous layer extracted with DCM (2 x 2 mL). The organic layers were combined and washed with water (2 x 5 mL), brine (2 x 5 mL) and dried over MgSO₄. The MgSO₄ was removed by filtration and the volatiles removed under reduced pressure to give an oil.

Synthesis of (H) and (Q)

To a solution of Dess-Martin Periodinane (0.023 g, 0.055 mmol) in 1 mL MeCN at 5 °C was added a mixture of (M), (N), (O), and (P) (0.010 g, 0.037 mmol) as a solution in MeCN (1 mL). The mixture was placed under an atmosphere of argon and allowed to warm to room temperature while stirring overnight. When complete, a white precipitate had formed and the reaction was cooled in an ice-bath and diluted with 2 mL sat. NaHCO₃. The mixture was diluted with 10 mL of EtOAc and the solids removed by filtering through a plug of Celite. The mixture was transferred to a separatory funnel and the layers separated. The aqueous layer was extracted with EtOAc (2 x 5 mL) and the organic layers combined, washed with water (3 x 5 mL) and brine (1 x 10 mL) and then dried over Na₂SO₄. The Na₂SO₄ was removed by filtration and the volatiles removed under reduced pressure to give a mixture of (H) and (Q) as a light, yellow oil.

Example 19

Alternate Synthesis of (H) and (Q)




Alternate Synthesis of (H) and (Q)

To a -5 °C solution of (R) (0.200 g, 0.78 mmol) in pyridine (3 mL) was added 10% aqueous NaOCl (1.5 mL) dropwise at a rate such that the internal reaction temperature remained below -4 °C. After the addition of NaOCl was complete, the reaction flask was placed in a 0 °C bath and stirred for two hours. The mixture was then

diluted with EtOAc (10 mL), washed with water (2 x 10 mL), brine (2 x 10 mL) and dried over Na₂SO₄. The Na₂SO₄ was removed by filtration and the volatiles removed under reduced pressure to give the crude mixture of (H) and (Q). Purification by flash chromatography (20:1 hexanes/ EtOAc) gave (H) as an oil (0.059 g, 0.216 mmol) and (Q) as a solid (0.023 g, 0.085 mmol).

Example 20

Synthesis of Compound 1



Synthesis of (F)

To a 10 mL round bottomed flask was added (H) (0.050 g, 0.18 mmol) and DCM (0.80 mL). The mixture was cooled to 0 °C and neat TFA (0.20 mL) was added dropwise. After the addition of TFA was complete the flask was allowed to warm to room temperature while stirring for one hour. The volatiles were then removed under reduced pressure and the resulting oil was chased with DCM (2 mL x 2) and the volatiles removed under reduced pressure.


Synthesis of Compound 1

To a 10 mL round bottomed flask containing (F) was added (E) (0.085 g, 0.15 mmol), MeCN (2.0 mL), HOBT (0.031 g, 0.23 mmol), and HBTU (0.087 g, 0.23 mmol) and the mixture was cooled to 0 °C. To this mixture was slowly added DIEA (0.077 g, 0.104 mL, 0.6 mmol) and the mixture was allowed to stir at 0 °C for one hour before quenching with saturated NaHCO₃ (5 mL). The mixture was diluted with EtOAc (15 mL)

and the layers were separated. The organic layer was washed with saturated NaHCO_3 (3 x 5 mL), brine (2 x 5 mL) and dried over Na_2SO_4 . The Na_2SO_4 was removed by filtration and the volatiles removed under reduced pressure to give a thick oil. To the flask containing the oil was added DCM (1 mL) and the placed under high vacuum while swirling giving Compound **1** (0.100 g, 0.14 mmol) as a foam.

Example 21

Synthesis of Compound **1**



Alternate Synthesis of (S)

To a 10 mL round bottomed flask was added (G) (0.055g, 0.18 mmol), formic acid (2 mL), and Pd/C (5% wt, 0.05 g). Once the deprotection was deemed complete by TLC and LCMS, the volatiles were removed under reduced pressure. The oil was chased with DCM (2 mL x 2) and the volatiles removed under reduced pressure.


Synthesis of Compound **1**

To a 10 mL round bottomed flask containing (S) was added (E) (0.085 g, 0.15 mmol), MeCN (2.0 mL), HOBT (0.031 g, 0.23 mmol), HBTU (0.087 g, 0.23 mmol) and the mixture was cooled to 0 °C. To this mixture was slowly added DIEA (0.077 g, 0.104 mL, 0.6 mmol). The mixture was then allowed to stir at 0 °C for 60 minutes and was quenched by the addition of saturated NaHCO_3 (5 mL). The mixture was diluted with EtOAc (15 mL) and the layers separated. The organic layer was washed with saturated NaHCO_3 (3 x 5 mL), brine (2 x 5 mL) and dried over Na_2SO_4 . The Na_2SO_4 was removed

by filtration and the volatiles removed under reduced pressure to give a thick oil. To the flask containing the oil was added DCM (1 mL) and the mixture placed under high vacuum while swirling giving Compound **1** as a foam.

Example 22

5 Synthesis of (H)



Water (214 mL) was added to a three neck flask equipped with a mechanical stirrer, an addition funnel, and a thermocouple with display and cooled to an internal temperature of -5 to 0 °C. Solid calcium hypochlorite (107 g, 748 mmol) was then added over approximately 5 minutes, while the temperature of the mixture is maintained at approximately -5°C to 0°C. The mixture was then further cooled to -10°C to -5°C and stirred for 10 minutes followed by addition of NMP (1000 mL) via addition funnel at a rate to maintain internal temperature between -10 °C to -5 °C. The reaction slurry was then stirred at -10 °C for 15 minutes. (R) (47.8 g, 187 mmol) was dissolved in NMP (400 mL) and added dropwise to the reaction mixture while maintaining the internal temperature between -15 °C and -10 °C. The reaction mixture was then stirred at -5 °C to 0 °C until the reaction was complete by TLC. Upon reaction completion, the mixture was quenched by slow addition of 1.0 M sodium thiosulfate solution (500 mL), maintaining an internal temperature of -10 °C to -5 °C. Ethyl Acetate (1000 mL) was then added, the layers were separated and the aqueous layer was extracted twice more. The combined organic layers were washed with water (500 mL) and brine (500 mL), dried over magnesium sulfate, filtered and concentrated under reduced pressure to a yellow oil which was dissolved in hexanes (600 mL) and filtered through a plug of silica to provide (H) as a pale yellow oil (20.8 g).

25

Equivalents


Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the compounds and methods of use

thereof described herein. Such equivalents are considered to be within the scope of this invention and are covered by the following claims.

All of the above-cited references and publications are hereby incorporated by reference.


CLAIMS

1. A method for the preparation of a crystalline compound of Formula (III),



wherein X is trifluoroacetate, comprising

- (i) preparing a solution of a compound of Formula (IV) in an organic solvent, wherein PG is a suitable protecting group



- (ii) adding a suitable acid;
(iii) bringing the solution to supersaturation to cause formation of crystals; and
(iv) isolating the crystals.

2. A method of claim 1, wherein PG is selected from Boc and Cbz and X is trifluoroacetate.

3. A method of claim 1 or 2, wherein the organic solvent is selected from dichloromethane, ethyl acetate, isopropyl acetate, isobutyl acetate, butyl acetate, propyl acetate, diethyl ether, methyl tert-butyl ether (MTBE), or any combination thereof.

4. A method of claim 3, wherein the organic solvent is selected from dichloromethane, ethyl acetate, MTBE, or any combination thereof.


5. A method of any one of claims 1 to 4, wherein bringing the solution to supersaturation comprises addition of an anti-solvent, allowing the solution to cool, reducing the volume of the solution, or any combination thereof.

6. A method of claim 5, wherein bringing the solution to supersaturation comprises adding an anti-solvent, cooling the solution to ambient temperature or lower, and reducing the volume of the solution.

7. A method of claim 5 or 6, wherein the anti-solvent is hexanes or heptanes.

8. A method of any one of claims 1 to 7, further comprising washing the crystals.

9. A method of claim 8, wherein the washing comprises washing with an anti-solvent, dichloromethane, ethyl acetate, or any combination thereof.
10. A method of claim 9, wherein washing comprises washing with anti-solvent.
11. A method of claim 10, wherein the anti-solvent is heptanes.
12. A method of any one of claims 1 to 11, wherein isolating the crystals comprises filtering the crystals.
13. A method of any one of claims 1 to 12, further comprising drying the crystals under reduced pressure.
14. A crystalline compound having a structure of Formula (III)



wherein X is trifluoroacetate.

15. A crystalline compound of claim 14, having a DSC thermogram substantially as shown in Figure 9.
16. A crystalline compound of claim 14 or 15, having an XRPD pattern substantially as shown in Figure 10.
17. A crystalline compound of any one of claims 14 to 16, having 2θ values 8.84; 15.18; 15.32; 16.20; 16.82; 17.66; 18.26; 19.10; 21.20; 22.58; 23.06; 23.52; 25.32; 26.58; 28.60; 30.08; 30.48; 30.84; 32.20; 36.14; 37.12.